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ABSTRACT 
 
Alzheimer’s disease is a neurodegenerative condition that is the leading cause of dementia in the 
elderly, which affected close to 50 million people worldwide in 2017. The disease is characterised by 
the presence of amyloid beta plaques and neurofibrillary tangles of hyperphosphorylated tau protein 
in the brain. There are no disease-modifying treatments, largely because the mechanisms underlying 
disease and pathology are not understood. It is estimated that common genetic variants explain ~33% 
of disease incidence, although the mechanism behind their action is not clear. Polymorphisms in the 
APOE gene have been widely linked with AD, and the APOE ε4 variant is the greatest genetic risk 
factor for sporadic Alzheimer’s disease.  
 
We hypothesise that epigenetic differences, namely DNA methylation, in APOE may contribute to 
Alzheimer’s disease aetiology and that this may also be related to APOE genotype. In this thesis we 
have investigated DNA methylation in prefrontal cortex and temporal gyrus tissue form individuals 
with varying degrees of pathology or disease using data from the Illumina 450K methylation array. We 
identified pathology-associated hypomethylation of APOE in four probes that reside in a CpG island in 
the 3’ untranslated region. Using a large cohort of pre-natal and post-natal brain tissue samples from 
individuals with methylation and matched genotype data we showed that methylation of one site in 
this region seems to be driven by APOE ε4 genotype in pre-natal development, although this was not 
observed in post-natal samples. We did however identify another loci in this island that showed 
hypomethylation with age in post-natal samples. In the promoter at the 5’ end of the gene we 
observed three adjacent loci near the transcription start site and one loci in the gene body that were 
significantly hypomethylated with advancing age in Alzheimer’s disease samples. Overall APOE ε4 
genotype had little effect on APOE DNA methylation in the context of Alzheimer’s disease. This 
project is the first large-scale study of APOE DNA methylation with respect to Alzheimer’s disease 
diagnosis and pathology, age and APOE genotype and highlights the need for further work in to the 
role of APOE DNA methylation in disease aetiology. 
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CHAPTER 1 : INTRODUCTION 
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1.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is the main cause of 
dementia, accounting for ~60-80% cases worldwide (Ashraf et al., 2016). It is clinically characterized 
by three primary groups of symptoms encompassing different aspects of the disease; cognitive 
dysfunction (deterioration of memory, executive function, speech, and other areas of cognition), non-
cognitive symptoms (including psychosis, emotional instability and agitation) and decline of 
instrumental and basic skills for activities in daily life, along with general deterioration of motor control 
and autonomic functions (Burns and Iliffe, 2009). Eventually, patients become incapable of 
independent living, and are wholly dependent on caregivers. AD is invariably fatal, often due to 
comorbid conditions such as dysphagia and aspiration pneumonia, and is the sixth leading cause of 
death in the United States, afflicting around 5.7 million people and projected to rise to nearly 14 
million by 2050 (Alzheimer’s Association, 2015) . A steady exponential growth in the incidence of 
dementia is expected worldwide, with epidemiological studies estimating a doubling of new cases 
every 20 years up to 2040 and a 15-fold increase in dementia prevalence in the 60-85 year old age 
group (Mayeux and Stern, 2013). This coincides with the Centre for Disease Control (CDC)’s estimate 
that the over 65 years population in the US will double over four decades, from 46.5 million in 2014, to 
83.7  million (Matthews et al., 2018). This inevitable rise in the geriatric population, and consequently 
AD prevalence, threatens to overwhelm healthcare services due to the inordinate financial and 
resource cost of caregiving (Matthews et al., 2018).  
 
1.1.1  AD neuropathology 
The neuropathology of AD is defined by the accumulation of dense, insoluble extracellular plaques 
composed of aggregated amyloid-beta (Aβ) and intracellular neurofibrillary tangles (NFT) of 
hyperphosphorylated tau protein. Aβ is formed from the amyloidogenic cleavage of the amyloid 
precursor protein (APP) by β-secretase and then γ-secretase. These Aβ monomers form oligomers 
and ultimately plaques. The spread of the NFTs through neural structures is measured with the Braak 
staging system, on a scale of I (mild lesions exclusive to the transentorhinal region) to VI (lesions are 
visible even in the occipital neocortex) (Braak et al., 2006). The presence of Aβ plaques and NFTs are 
believed to lead to neuronal cell and synapse loss, especially the cholinergic neurons that connect the 
hippocampus and cerebral cortex and play a critical function in memory encoding/recall (Niikura, 
Tajima and Kita, 2006), though recent neuronal cell studies have shown Aβ oligomers to have a 
pathogenic role in their own right by instigating cell-cycle events (Mukhin, Pavlov and Klimenko, 2017) 
(Varvel et al., 2008), with further gene-knockout studies suggesting their reliance on tau for signalling 
(Seward et al., 2013). This process is observed as progressive atrophy and shrinkage within the 
cerebral cortex and several subcortical regions such as the entorhinal cortex, temporal gyrus, and 
hippocampus.  
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1.1.2  Diagnosis of AD 
The established criteria for AD diagnosis are confirmed to have high sensitivity and specificity, with an 
80% positive predictive value (Cummings, 2012). Central aspects as delineated in NINCDS-ADRDA, 
the most commonly used set in AD research, include severe cognitive deficits and functional 
compromise characteristic of dementia shown by neuropsychological testing, confirmation of 
diagnosis with post mortem examination, and definitive exclusion of other forms of dementia 
(Cummings, 2012). 
 
However, improved in-vivo biomarker detection has revealed neurological damage insidiously 
beginning and worsening decades before clinical diagnosis (Huynh and Mohan, 2017), placing earlier 
and better methods of detection/diagnosis as the foremost priority. Another pertinent problem is 
accurately determining whether potential dementia patients will develop the condition, and also 
differentiating those with preclinical dementia into future AD and non-AD sufferers (Knopman and 
Caselli, 2012) (Nitrini, 2010) (B.J., 2015). One of the earliest potential presentations of AD is mild 
cognitive impairment (MCI), an intermediate stage where individuals have memory impairment with 
little impact on general cognition and capability in daily tasks (B.J., 2015) However, it is by itself an 
unreliable indicator of future development of dementia, as controversy exists over subjective 
differentiations from normal cognitive dysfunction observed in ageing (Masters, Morris and Roe, 2015) 
, as well as the lack of guaranteed development of AD in patients (Masters, Morris and Roe, 2015). 
Furthermore, MCI can be a common precursor shared with other forms of dementia such as vascular 
dementia. 
 
The majority of pathological facets of AD remain difficult to quantify clinically ante mortem, which 
creates a divide between symptom-based and pathological diagnosis (Hane, Lee and Leonenko, 
2017), especially as multiple aggregated protein species can cause similar disease phenotypes 
(Villemagne et al., 2018). The gold standard remains to be post mortem histological analysis of 
neuropathology, looking for the presence of Aβ plaques and quantifying the spread of NFTs using 
Braak staging (Perl, 2010), to confirm a clinical diagnosis. However, even this direct method is fallible 
due to possible co-existance of other proteins with tau and Aβ (Villemagne et al., 2018).  
 
Cerebrospinal fluid (CSF) collection and blood sampling has been employed to directly measure 
biomarker levels in the nervous system and blood, respectively during life (Reitz & Mayeux, 2014). 
Recent advances in neuroimaging have also allowed alternative non-invasive visualisation of changes 
within the brain itself, which are also highly specific. Structural and functional magnetic resonance 
imaging (sMRI/fMRI) have been employed to identify gross changes in brain regions and metabolism, 
respectively, although these are not particularly useful at identifying pre-clinical AD-related changes in 
brain structure (Johnson et al., 2012). Positron emission tomography (PET) has been combined with 
new markers in recent years, to allow the assessment of amyloid (Herholz and Ebmeier, 2011) and 
Tau (Wang et al., 2016) levels directly within the brain. However, there are specific limitations to using 
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neuroimaging, such as incomplete visualisation of certain aspects of pathology for each method and 
expensive costs, which hinder their use clinically for diagnosis (Johnson et al., 2012).  
 
1.1.3  Treatments for AD 
As of yet, there are no effective treatments that can halt or reverse dementia development.  Current 
medications simply treat the symptoms of the disease, but do not reverse the underlying pathology. 
This is in part because the disease is currently diagnosed only when clinical symptoms of the disease 
emerge, by which point considerable pathology has already occurred during the preclinical stage, and 
in part because we do not know the exact cause of the majority of AD cases (Hane, Lee and 
Leonenko, 2017). The main class of drugs currently prescribed for AD are acetylcholinesterase 
inhibitors (e.g. Donepezil, Galantamine, Rivastigmine), often in conjunction with memantine, a 
glutamate antagonist (Herrmann et al., 2013). The former reduce symptoms such as memory deficits 
by decreasing breakdown of the neurotransmitter acetylcholine, compensating for damage to 
cholinergic neural networks in AD, with the majority of patients experiencing mild to moderate 
improvement with few side effects (Casey, Antimisiaris and O’Brien, 2010) (Mehta, Adem & Sabbagh, 
2012), though drug therapies are ultimately highly individualised with no universal points of initiation 
and discontinuation (Hogan, 2015). Research efforts have focused on developing new pharmaceutical 
treatments such as immunotherapy drugs against Aβ or tau, which would aim to galvanise the 
immune system to clear these neuropathological hallmarks in the CNS, although their root cause is 
still undetermined (Herrmann et al., 2013). Clinical trials have been unsuccessful so far as lost neural 
networks cannot recuperate merely by eliminating pathology, though more promise has been shown 
in early treatment of mild cases, leading to a shift in preventative treatment (Hane, Lee and Leonenko, 
2017). 
 
1.1.4  Types of AD 
The elderly are most at risk of developing the disease in the form of late-onset AD (LOAD), which 
affects 13% of people 65 years and older, and its incidence is generally agreed to expand 
exponentially with age (Naj, A.C. et al., 2014). LOAD tends to be sporadic, with no defined aetiology. 
A small proportion of AD cases are familial (1-6%) (Bekris et al., 2010), and are caused by autosomal 
dominant mutations in APP, Presenilin (PSEN) 1 or PSEN2, which encode key components of the γ-
secretase enzyme, which cleaves APP. Familial AD tends to occur in patients below 65 years of age, 
which are referred to as early-onset AD (EOAD)  (Bekris et al., 2010). 
 
1.1.5  A role for genetic mechanisms in AD 
The molecular mechanisms underlying sporadic AD aetiology are poorly defined. Quantitative genetic 
analyses, such as twin-studies have demonstrated high heritability estimates (58%-79%) for AD in 
monozygotic (MZ) twins and higher concordance in MZ than in dizygotic (DZ) twins (Gatz et al., 
2006), which prompted initial approaches to AD aetiology to focus on uncovering a genetic 
contribution to disease susceptibility. 
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Genome-wide association studies (GWAS) have been critical in identifying genetic variation linked 
with disease, with many common-sequence variations in risk genes being classified. A recent meta-
analysis of AD GWAS has highlighted a number of susceptibility loci that reach genome-wide 
significance (Table 1.1). Many of these play important roles in neural repair, immunological and 
metabolic pathways, and have also been implicated in the development of other neurodegenerative 
diseases (Lambert et al., 2013). Currently, the most significant and well-established LOAD-risk GWAS 
loci is the polymorphism of the apolipoprotein E gene (APOE) (Foraker et al., 2015), whose product is 
a glycoprotein that plays a key role in lipid metabolism as a transporter of lipoprotein and cholesterol. 
The gene has three main alleles; APOE ε2, ε3, and ε4, of which ε4 is the most well-established 
genetic risk factor for development of LOAD, with a frequency of ~40% in patients (Liu et al., 2013). 
Individuals with one APOE ε4 allele have a high odds ratio for developing AD (2.6-3.2), which is 
further boosted to 14.9 by a second ε4 allele (Liu et al., 2013). Interestingly, APOE ε2 is known to be 
protective, with individuals with two APOE ε2 alleles having an OR for AD of only 0.6 (Liu et al., 
2013). Although the three isoforms of the allele differ by only one or two amino acids (Table 1.2), 
possession of the ε4 allele has been linked to decreased amyloid fragment clearance in neurons, and 
subsequently a greater likelihood of plaque formation, along with increased probability of cerebral 
amyloid angiopathy (CAA) and age-related cognitive decline during normal ageing.  The mechanisms 
behind amplified disease risk with the APOE ε4 protein isoform are currently poorly understood, and 
cannot be identified by DNA sequence analysis alone. New hypotheses suggest its role in AD 
pathology may be related to its modulation of amyloid precursor protein (APP), such as catalysing its 
cleavage by β- and γ- secretase and promoting its transcription (Huang et al., 2017).  Although APOE 
is the most well-established common genetic variant for AD, genetic analyses cannot completely 
account for the problem of ‘missing heritability’ in disease. Collectively all common variants only 
account for about a third of disease incidence (Ridge et al., 2016). Recent studies have used whole 
genome or exome sequencing to identify rare variants with a larger effect size, and such studies have 
nominated single nucleotide polymorphisms (SNPs) in gene such as TREM2 (Jonsson et al., 2013) 
(Guerreiro et al., 2013) and PLD3 (Blanco-Luquin et al., 2018). One particular issue with the SNPs 
that have been associated with AD to date is that for the majority of genes no clear mechanisms 
behind their actions has been established and mutations are often found in non-coding regions of the 
genome (Giri, Zhang and Lü, 2016) (Tansey, Cameron and Hill, 2018).  
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Table 1.1 - Summary table of SNPs associated with AD, which reached genome wide 
significance in a recent meta-analysis  
(Taken from Lambert et al., 2013). Abbreviations: Chr. = Chromosome 
SNP Chr:Position Closest Gene Odds Ratio 
rs6656401 1:207692049 CR1 1.18 
rs6733839 2:127892810 BIN1 1.22 
rs10948363 6:47487762 CD2AP 1.1 
rs11771145 7:143110762 EPHA1 0.9 
rs9331896 8:27467686 CLU 0.86 
rs983392 11:59923508 MS4A6A 0.9 
rs10792832 11:85867875 PICALM 0.87 
rs4147929 19:1063443 ABCA7 1.15 
rs3865444 19:51727962 CD33 0.94 
rs9271192 6:32578530 HLA-DRB5– HLA-DRB1 1.11 
rs28834970 8:27195121 PTK2B 1.1 
rs11218343 11:121435587 SORL1 0.77 
rs10498633 14:92926952 SLC24A4 / RIN3 0.91 
rs8093731 18:29088958 DSG2 0.73 
rs35349669 2:234068476 INPP5D 1.08 
rs190982 5:88223420 MEF2C 0.93 
rs2718058 7:37841534 NME8 0.93 
rs1476679 7:100004446 ZCWPW1 0.91 
rs10838725 11:47557871 CELF1 1.08 
rs17125944 14:53400629 FERMT2 1.14 
rs7274581 20:55018260 CASS4 0.88 
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Table 1.2 - Single nucleotide polymorphisms (SNPs) that give rise to specific APOE alleles  
(Taken from Foraker et al., 2015) 
 
 
 
 
 
 
1.2 Epigenetics 
Epigenetics refers to the reversible, mitotically and meiotically heritable regulation of gene expression, 
independent of DNA sequence variation (Lord, Lu and Cruchaga, 2014). Established epigenetic 
mechanisms include DNA modifications, modifications of histone proteins of nucleosomes and 
microRNAs (miRNAs). The most highly characterised and stable epigenetic modification is DNA 
methylation of the pyrimidine ring of cytosine to form 5-methylcytosine (5mC) in CpG dinucleotides, 
which are often clustered together in CpG islands (CGI) within the genome. These marks are 
regulated by DNA methyltransferase enzymes (DNMTs), with DNMT1 responsible for maintenance of 
patterns and DNMT3A and B responsible for de-novo modification (Deaton and Bird, 2011). They 
were traditionally thought to be inhibitory of transcription as the addition of the methyl group was 
thought to prevent the binding of transcription factors and draw methyl-binding proteins to alter 
chromatin structure, shifting it into a transcriptionally-inactive compact state (heterochromatin). 
However, recent evidence suggests that although this is the case for CpG rich regions in the 
promoters of constitutively expressed housekeeping genes (Deaton and Bird, 2011) (Vavouri and 
Lehner, 2012), DNA methylation can have alternative effects on gene expression. DNA methylation 
has been shown to have downstream effects on gene splicing; exons have higher levels of DNA 
methylation than flanking introns, with 22% of the splicing of alternative exons being epigenetically 
regulated as RNA polymerases bind to methyl groups (Lev Maor, Yearim and Ast, 2015).   
 
The presence of hydroxymethylated cytosines (5hmC), produced via catalysis of 5mC by ten-eleven 
translocation (TET) proteins was initially thought to be an intermediate marker of demethylation. 
However, recent research suggests it may be an independent marker with unique transcription 
regulatory roles of its own (Kroeze, van der Reijden and Jansen, 2015). New methodologies such as 
oxidative bisulfite sequencing (Booth et al., 2013) and reduced representation hydroxymethylation 
profiling (RRHP) (Ellison, Bradley-Whitman and Lovell, 2017) have facilitated the measurement of 
5hmC in isolation.  
1.2.1  Methylation Quantitative Trait Loci (mQTL) 
Genetic variation such as SNPs at specific loci may influence patterns of DNA methylation across 
genomic regions, both in cis and in trans (though primarily the former). They are referred to as 
methylation quantitative trait loci (mQTLs) and are enriched in regulatory chromatin domains and 
transcription-factor binding sites, altering gene expression via transcription 
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enhancement/suppression, and potentially alternative mRNA splicing, through methylation (Gutierrez-
Arcelus et al., 2015). As epigenetic associations with gene expression have been found to be more 
tissue-specific compared to genome sequence variation (Gutierrez-Arcelus et al., 2015) and mQTLs 
are heavily associated with genetic variants (Hannon et al., 2018), they may be one mechanism by 
which genetic variants in non-coding regions may exert functional changes by tissue-specific 
epigenetic mediation. Additionally, the elaborate network of pleiotropic associations between complex 
traits, DNA methylation sites and gene variants (Hannon et al., 2018) present an intriguing opportunity 
to dissect complex disease phenotype development and refine GWAS analyses for risk loci. They 
have also become a subject of interest in neuromedicine, as brain mQTLs show significant overlap 
with genetic variants associated with gene-expression in the brain (Hannon et al., 2015), with many 
psychiatric-disease linked SNPs revealed to cause methylation differences dysregulating genes 
critical for neurological development/function (Ciuculete et al., 2017). They are thus implicated in 
magnifying risk of developing schizophrenia and other psychiatric disorders (Hannon et al., 2015) 
(Ciuculete et al., 2017). An example of an mQTL is shown in Figure 1.1. 
 
Figure 1.1- An example schematic of an mQTL. In this example individuals homnozygous for 
allele 1 have less DNA methylation at this specic CpG than individuals who are 
heterozygous, or homozygous for allele 2.	
 
 
1.2.2  Epigenome-wide association studies (EWAS) of AD 
Epigenome-wide association studies (EWAS) are a recent development allowing the profiling of 
genome-wide DNA methylation patterns in AD (Table 1.3). The first EWAS in LOAD was conducted 
with the Illumina Infinium 27K Methylation BeadChip array (27K array) and identified 948 CpG sites, 
mapping to 918 unique genes that were associated with disease in the frontal cortex (Bakulski et al., 
2012). The most significant loci resided in TMEM59. Similar analyses of hippocampal tissue with 
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varying degrees of Braak-stage pathology demonstrated DNA methylation alterations in four loci 
distributed between the DUSP22, CLDN15 and QSCN6 genes (Sanchez-Mut et al., 2014). More 
recent studies have utilised the Illumina Infinium 450K Methylation BeadChip array (450K array) to 
determine disease-associated differential DNA methylation at >485,000 CpG sites. Lunnon et al used 
this technology to assess differential methylation associated with Braak stage across a number of 
tissues, including cortex (entorhinal cortex (EC), prefrontal cortex (PFC) and superior temporal gyrus 
(STG)), cerebellum and blood in ~120 individuals (Lunnon et al., 2014). Meanwhile, De Jager and 
colleagues used this technique to identify differential DNA methylation associated with neuritic plaque 
burden in PFC in >700 individuals (De Jager et al., 2014). Interestingly, both of these studies 
highlighted significant differentially methylated positions (DMPs) in the same four CpG sites in the 
genes ANK1, RPL13, RHBDF2 and CDH23 (Lord, Lu and Cruchaga, 2014). A more recent EWAS 
has highlighted significant DNA hypermethylation associated with increasing Braak stage across a 
48kb region of the HOXA gene cluster (Smith et al., 2018). Recently, DNA hydroxymethylation 
patterns in AD have also been assessed by EWAS, one study of the prefrontal cortex identified 517 
plaque-associated and 60 NFT-associated differentially hydroxymethylated regions (Zhao et al., 
2017). Another recent novel development has been EWAS of DNA methylation alterations in AD in 
isolated neuronal and non-neuronal nuclei, allowing the identification of cell type-specific methylation 
patterns (Gasparoni et al., 2018). 
 
1.2.3  Epigenetic differences in APOE in AD 
The APOE genomic region contains a single well-defined CGI spanning 880 base pairs (bp) in length 
with 90 CpG sites, overlapping with the last exon of the gene, spanning from the 3’ end of intron 3 and 
and ending in the 3’ untranslated region of exon 4 (Figure 1.2). This area contains the two SNPs that 
define APOE allele type, rs429358 and rs7412 (Table 1.2). Another SNP, rs405509, is located in the 
promoter region, and has been suggested to increase DNA methylation in light of its inhibitory effect 
on gene transcription, with these findings supported by higher methylation levels for carriers of the 
rs405509 A and ε4 alleles (Ma et al., 2015). Differential methylation of the APOE CGI has been 
observed in AD-affected brain tissue (Foraker et al., 2015), where it may play a crucial role in 
pathology. Interestingly, this does not seem to be restricted to AD, and a recent study has shown 
altered DNA methylation in APOE in Dementia with lewy bodies (DLB) (Tulloch, Leong, Chen, et al., 
2018). As previously discussed, Smith et al, recently published an EWAS that identified significant 
Braak-associated DNA hypermethylation of the HOXA gene cluster in PFC (Smith et al., 2018). 
Interestingly, the authors also profiled the STG in the same individuals, and noted two CpG sites 
(cg05501958 and cg21879725) in the APOE gene that showed significant Braak-associated 
hypermethylation of the APOE gene (Lunnon, Personal communication). These two loci reside close 
to the SNPs that determine APOE genotype.  
 
Given that APOE currently represents the genetic variant associated with sporadic AD with the 
greatest disease risk, we hypothesise that altered DNA methylation in AD may be one mechanism by 
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which APOE genotype exerts a biological effect. There are 13 probes on the 450K array that map to 
the APOE gene. To address my hypothesis I will investigate an association of APOE DNA methylation 
at these probes with Braak stage or disease diagnosis in all available AD EWAS. Subsequently, I will 
perform a mQTL analysis to examine the data with respect to APOE genotype and to determine 
whether any disease-associated differences may be caused by genetic differences between 
individuals with AD and controls. Finally, I will access matched GWAS and EWAS data collected from 
~1000 individuals across the life span (from foetal development to centenarians). This will allow me to 
investigate the mQTL in individuals with APOE ε4 alleles and no AD, and also to investigate whether 
there is any association with the mQTL and advancing age.  
 
This project is of particular interest as it will be the first large-scale study to investigate the 
mechanisms by which APOE genotype may affect gene regulation. Furthermore, given that epigenetic 
differences are potentially reversible, it could potentially identify novel targets for future 
pharmacological intervention.  
 
Figure 1.2 - Gene structure of APOE 
(Foraker et al., 2015) 
 
 
 
 
 
 
 
 
 
 
 
 
Aims 
1. To analyse DNA methylation in the APOE gene in all available DNA methylomic 
studies of AD 
2. To determine whether DNA methylation differences in APOE in AD are due to a 
mQTL in the gene 
3. To investigate whether APOE DNA methylation differences due to the mQTL are 
stable, or altered over the life course 
 
cg21879725 
cg18799241 
cg05501958 
cg16471933 
cg06750524 
cg19514613 
cg18768621 
cg08955609 
cg12049787 
cg26190885 
cg01032398 
cg04406254 
cg14123992 
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CHAPTER 2 : MATERIALS AND METHODS 
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2.1 Available EWAS datasets 
 
2.1.1  AD EWAS datasets 
Previously generated DNA methylation data was obtained from four independent EWAS datasets of 
AD, which all used the 450K array. Although for some cohorts data was available from multiple 
tissues, we focused our analyses on data from the PFC or temporal gyrus (TG) (STG or middle 
temporal gyrus (MTG)), as either one or both of these regions was available for all four datasets. Our 
cohorts were as follows: 
1. The “London” cohort consisted of EWAS data from 117 individuals generated by Lunnon et al 
(Lunnon et al., 2014). This included data generated in both the PFC and STG from individuals 
archived in the MRC London Neurodegenerative Disease brain bank and is available under gene 
expression omnibus (GEO) accession number GSE59685. 
2. The “Mount Sinai” cohort consisted of EWAS data from 147 individuals generated by Smith et al 
(Smith et al., 2018). This included data generated in both the PFC and STG from the Mount Sinai 
Alzheimer’s Disease and Schizophrenia Brain Bank and is available under GEO accession 
GSE80970. 
3. The “ROS/MAP” cohort consisted of EWAS data from 740 individuals by De Jager et al (De 
Jager et al., 2014). This was generated in the PFC from the Religious Orders Study and the 
Rush Memory and Aging Project and was provided direct from the authors. 
4. The “Arizona” cohort consisted of EWAS data from 404 individuals generated by Professor Paul 
Coleman (Personal Communication). This included data generated in the MTG from individuals 
archived in the Banner Sun Health Research Institute Brain and Tissue Bank. This data is 
currently unpublished data and was provided to us as part of an ongoing collaboration.  
In total we utilized data from 1408 unique individuals, which equated to 996 PFC samples and 665 TG 
samples, and for 259 donors we had matched data from both the PFC and TG (Table 2.1). We used 
Tri-allelic Exact test for Hardy Weinberg Equilibrium (HWE) to investigate whether APOE genotypes 
were different to the general population. We saw a nominally significant difference to the general 
population in the Arizona cohort (P = 0.047), but not the London, ROSMAP or Mount Sinai cohorts (P 
>0.05). Demographics for each individual cohort, and information such as age, sex and Braak stage 
can be found in Table 2.2. 
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Table 2.1 - AD EWAS sample numbers available for each cohort by tissue. 
Source of EWAS data  
PFC EWAS 
data 
TG EWAS 
data 
Total independent 
donors 
London (Lunnon et al., 2014) 114 117 117 
Mount Sinai (Smith et al., 2018) 142 144 147 
ROS/MAP (De Jager et al., 2014) 740 - 740 
Arizona (Coleman et al, Unpublished) - 404 404 
TOTAL 996 665 1408 
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Table 2.2 - Demographics for individual cohorts used in the AD study.  
Shown for all four cohorts are the number of control samples (Braak 0-II), and AD samples (Middle stage AD (Braak III-IV) and Late stage AD 
(Braak V-VI)). Shown for each group are mean age at sampling ± standard deviation (SD), number of males (M) and females (F), Braak stage, 
Number of APOE ε4 alleles (0,1,2 or unknown [N/A]) and brain regions investigated. 
 Cohort London Mount Sinai ROS/MAP Arizona 
 Disease stage Control Middle Stage 
Late 
Stage Control 
Middle 
Stage 
Late 
Stage Control 
Middle 
Stage 
Late 
Stage Control 
Middle 
Stage Late Stage 
Number of samples 29 18 66 60 43 44 146 413 161 81 144 176 
Age at death (±SD) 
77.6 
(12.80) 
88.5 
(5.20) 
85.4 
(8.13) 
82.0 
(7.56) 
82.7 
(6.55) 
88.0 
(7.53) 83.0 (6.08) 86.9 (4.09) 
87.9 
(3.45) 
80.8 
(7.64) 
86.8 
(6.39) 82.6 (8.29) 
Sex (M/F) 13/16 7/11 26/40 32/28 13/30 12/32 73/73 146/267 45/116 54/27 72/72 76/100 
Braak stage 0-II III-IV V-VI 0-II III-IV V-VI 0-II III-IV V-VI 0-II III-IV V-VI 
 No APOE ε4 
alleles (0/1/2/NA) 19/6/1/3 8/7/0/3 
13/36/11/
6 44/10/0/6 25/11/0/7 21/18/5/0 121/25/0/0 323/84/6/0 86/72/3/0 64/14/2/1 98/38/3/5 68/83/22/3 
Brain regions 
investigated PFC, TG PFC, TG PFC TG 
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2.1.2  Life course (“Big Brain”) EWAS dataset 
The Complex Disease Epigenomics Group at the University of Exeter has generated EWAS data on 
the 450K array for individuals across the life course from their ongoing studies into DNA methylation 
in a range of complex disorders, including autism spectrum disorder (ASD), schizophrenia, 
depression, MCI and age-matched controls. In addition, they have also generated 450K data on foetal 
brain samples (Spiers et al., 2015). For the purpose of the current study we utilised EWAS data from 
PFC for individuals in these various studies, and combined it with the foetal brain data and data from 
the AD study, to allow us to look at differences in methylation with age and in each cohort with 
genotype. Together this gave me EWAS data from 136 individuals (Table 2.3).  
 
Table 2.3 - Demographics for individual cohorts used in the life-course study.  
Shown are the number of control samples, number of males (M) and females (F), mean age ± 
standard deviation (SD), number of APOE ε4 alleles (0,1,2 or unknown [N/A]). *Please note for age, 
this is shown as days post conception for foetal brain EWAS, and in years for the other EWAS. 
Abbreviations: SCZ (schizophrenia), DEP (Depression), MCI (Mild cognitive impairment), SD 
(Standard deviation). 
	
  
Foetal 
Brain 
ASD  
cohort 
Schizophrenia 
cohort 
Depression  
cohort 
 
MCI cohort 
Control ASD Control SCZ Control DEP 
No. 
Samples 136 24 21 45 39 20 20 
 
618 
Sex (M/F) 77/59 18/6 18/3 35/10 26/13 16/4 15/5 237/881 
Age* 
(±SD) 
92.1 
(24.66) 
45.1 
(22.5) 
25.5 
(19.5) 
56.1 
(19.7) 
54.6 
(18.1) 
39.4 
(19.5) 
48.6 
(20.8) 
87.0 (4.96) 
No. APOE 
ε4 alleles 
(0/1/2/NA) 
85/43/3/
0 
18/6/0/
0 
13/7/1/
0 
31/12/2/
0 
29/8/0/
0 
18/2/0/
0 
18/2/0/0 
 
 
442/136/9/3
1 
29	
	
2.2 DNA Methylomic profiling 
2.2.1  450K array 
The Illumina Infinium Human Methylation BeadChip array is a high-throughput, cost-effective method 
of quantifying genome-wide levels of DNA methylation at specific genomic loci. The 450K array is 
capable of assaying 485,764 CpG sites with a combination of the type I probes used in its 
predecessor (27K array) and a new type II probe. All EWAS datasets described in section 2.1 were 
generated on the 450K array. The EWAS data was all generated prior to the start of this project. 
However, the methods for generating this data were the same across all studies and were as follows. 
First, DNA was extracted from brain tissue, and the quantity and quality assessed using the Nanodrop 
Spectophotometer and gel electrophoresis, respectively. Only high molecular weight (Mw) DNA was 
then taken forward to the 450K arrays. Second, 500ng DNA was bisulfite treated using the Zymo EZ-
96 DNA Methylation-Gold TM Kit (Cambridge Bioscience, cat no.: D5007) and eluted in 20µl buffer. 
This process converts unmodified cytosines to uracils whilst modified cytosines remains as cytosines. 
The sequence can then be amplified via subsequent PCR, resulting in all uracil residues being 
amplified as thymine and only modified cytosine residues being amplified as cytosine. Quality control 
(QC) checks were then performed using PCR to check bisulfite conversion. Third, all samples were 
processed using 450K array (Illumina Inc, CA, USA) according to the manufacturer’s instructions, with 
minor amendments and quantified using an Illumina HiScan System (Illumina, CA, USA). In this 
process the denatured DNA undergoes whole-genome amplification to uniformly increase the amount 
of DNA by several orders of magnitude while preventing amplification bias. The samples are then 
fragmented and deposited on the BeadChip arrays and incubated in an Illumina Hybridisation oven to 
stimulate hybridising of probes to the chip, which is then washed to remove any nonspecifically and 
unsuccessfully hybridised DNA. The oligonucleotides are then extended and stained in capillary flow-
through chambers to apply fluorphores. These are excited by the laser of the Illumina HiScan 
system(Illumina, San Diego, CA, USA), which then records high resolution images of the fluorescent 
intensity. 
 
2.2.2  450K array normalisation and QC 
Signal intensities were imported into R using the methylumi package (Davis and Bilke, 2018) as a 
methylumi object. The DNA modification level at each studied CpG site is determined by calculating 
the ratio of fluorescent intensity for modified and unmodified probes, producing a beta value for each 
site. The range of values spans from 0 (i.e. no modified cytosines at the site) to 1, (i.e. all cytosines 
are modified at that site), and can be interpreted as a percentage. Initial QC checks that were 
undertaken in the methylumi package for the various EWAS datasets included multi-dimensional 
scaling of both X and Y chromosomes to assess concordance between sex as recorded on post-
mortem records and predicted sex using 65 control SNPs probes on the 450K array. The 65 SNPs 
were also used to confirm that matched PFC and TG data were sourced from the same individual. 
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One of the most important steps of analysing 450K array data when studying complex polygenic 
disorders is quantile normalisation (QN), in order to ensure optimal sensitivity when detecting 
differential DNA methylation due to technological shortcomings such as differences in accuracy and 
reproducibility between Infinium II and I probes within the 450K array. Beta values undergo this 
process to replace intensity scores with the mean of features from a single rank from each array, 
generating identical array-wide data distributions. All QN and data QC steps were performed using R 
3.4.3 (R Core Team 2018).  This was carried out using the dasen function in the R package 
wateRmelon (Pidsley et al., 2016). Within the package the pfilter function is used to remove samples 
where 5% of sites had a detection p-value > 0.05. Probes with common (minor allele frequency (MAF) 
> 5%) SNPs in the CpG or single base extension position, or probes that were nonspecific or miss-
mapped (Chen et al., 2013) were removed from downstream analyses. For the purpose of the current 
project normalised beta values for 13 probes that mapped to the APOE gene (Table 2.4, Figure 2.1) 
were taken forward for statistical analysis. For the Life course (“Big Brain”) EWAS dataset the probe 
cg18768621 did not pass QC and therefore we only examined the remaining 12 CpG sites in this 
dataset. 
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Table 2.4 - A list of all CG probes mapping to the APOE gene on the 450K array. 
Chromosomal positions (hg19), Illumina annotation (APOE), gene region, and respective 
CpG islands are shown. 
Probe Position 
Illumina 
Annotation Region CpG Island 
cg14123992 19:45,407,868 APOE TSS1500 chr19:45411720-45412600 
cg04406254 19:45,407,945 APOE TSS1500 chr19:45411720-45412600 
cg01032398 19:45,408,121 APOE TSS1500 chr19:45411720-45412600 
cg26190885 19:45,409,005 APOE TSS200 chr19:45411720-45412600 
cg12049787 19:45,409,080 APOE;APOE 1stExon;5'UTR chr19:45411720-45412600 
cg08955609 19:45,409,353 APOE 5'UTR chr19:45411720-45412600 
cg18768621 19:45,409,440 APOE 5'UTR chr19:45411720-45412600 
cg19514613 19:45,409,713 APOE 5'UTR chr19:45411720-45412600 
cg06750524 19:45,409,955 APOE Body chr19:45411720-45412600 
cg16471933 19:45,411,802 APOE Body chr19:45411720-45412600 
cg05501958 19:45,411,873 APOE Body chr19:45411720-45412600 
cg18799241 19:45,412,599 APOE 3'UTR chr19:45411720-45412600 
cg21879725 19:45,412,647 APOE 3'UTR chr19:45411720-45412600 
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Figure 2.1 - A gene map of APOE showing the position of its main 3' CpG island, along with location of all CpG probes mapping to the APOE 
gene on the 450K array. 
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2.3 APOE genomic profiling 
For the Arizona and ROS/MAP AD cohorts APOE genotype data was supplied from the data supplier 
as they had previously genotyped these samples for rs429358 and rs7412. For the London and 
Mount Sinai AD cohorts, and all the longitudinal EWAS datasets, APOE genotype was determined by 
imputing this from GWAS data collected in the same samples using Michigan imputation server using 
Minimac3 (Das et al., 2016). The 1000 Genomes Phase 3 (Version 5) was used as the reference 
panel for imputation (1000 Genomes Project Consortium, 2015). It has been demonstrated that 
imputing rs429358 and rs7412 using reference panels is very accurate and generates comparable 
results to directly genotyped samples (Radmanesh et al., 2014). 
 
2.4 Statistical analyses 
All data analysis scripts can be found in Appendix 1. 
2.4.1  Analysis of AD EWAS data 
All statistical analyses in this project were performed using R 3.4.3. To investigate DNA methylation 
differences at the 13 CpG sites in AD we performed a linear regression analysis in each AD EWAS 
cohort and within each tissue separately, looking for an association of DNA methylation with the 
variables of Braak score or AD (case/control) diagnosis, controlling for the co-variates of age, sex and 
cell-proportion. Cell proportion was estimated from the genome-wide methylation data for each EWAS 
cohort from the R package CETS (Guintivano, Aryee and Kaminsky, 2013). CpG methylation was 
expressed as percentages of methylated cells, derived from adjusted beta values. Effect sizes 
(coefficients) of variables were also calculated from these models, and used to quantify degrees of 
methylation of CpGs. “Nominal” significance was deemed to be when P <0.05, whilst our Bonferroni 
significance threshold was deemed to be P < 3.85E-3, to control for multiple testing across 13 CpG 
sites. Bonferroni assumes independence between all tests performed. However, due to the high 
correlation between DNA methylation at adjacent CpG sites and multiple tissues from the same 
individuals, the tests are not fully independent. Therefore, by using a Bonferroni significance threshold 
we are being overly conservative. However, we acknowledge that by performing tests across multiple 
cohorts and tissues, the significance threshold could have been adjusted for this. A Fisher’s combined 
probability test was conducted across all the AD cohorts within each tissue separately using the 
“MetaDE.pvalue” function in the package MetaDE (Wang et al., 2012).  
 
2.4.2  Analysis of Lifecourse “Big Brain” EWAS data 
To investigate DNA methylation differences at the 13 CpG sites with respect to age in brain samples 
over the life course we used a linear regression model to look for an association of DNA methylation 
with age, whilst controlling for the co-variates of sex, cell-proportion, brain region, diagnosis and brain 
bank. This was performed (a) within the foetal brain cohort and then (b) within all other (postnatal) 
samples. In this cohort the probe cg18768621 failed QC, and so we only analysed the remaining 12 
probes. As such, for this analysis our Bonferroni significance threshold was deemed to be P < 4.17E-
3, to control for multiple testing across 12 CpG sites. 
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2.4.3  Analysis of mQTLs 
The mQTL analyses used a linear regression analysis to look for an association of DNA methylation 
(at each probe individually) with the number of APOE ε4 alleles (0,1 or 2), whilst controlling for co-
variates. In the first mQTL analysis we looked in the PFC and STG separately for an association of 
DNA methylation with number of APOE ε4 alleles in the AD meta-analysis cohort, looking for an 
association (regardless of phenotype) at all 13 CpG sites individually, whilst controlling for the co-
variates of sex, cell proportion, brain region, diagnosis and cohort. Positive/negative differences 
between adjusted beta values of samples were used to represent corresponding effects on 
methylation by selected variables. We then repeated this analysis but stratifying the data by 
AD/control status to look to see if this was more apparent in AD or control samples. Next, we looked 
in the “Big Brain” EWAS data to look for an association of DNA methylation with the number of APOE 
ε4 alleles, individually at each of the 12 probes available in this cohort, whilst controlling for the co-
variates of sex, cell proportion, brain region, diagnosis and brain bank. We analysed the pre-natal and 
post-natal cohorts separately. 
 
2.4.4  Power 
 
Concerning Braak stage, we have 95% power to detect a 2.5% methylation difference between high 
and low Braak stage at a significance level of P < 3.85E-03 (Bonferroni), in the London cohort, with 29 
samples per group, and 100% power in the Mount Sinai cohort, with 44 samples per group. In the 
ROSMAP cohort, with 146 samples per group, we have 100% power and in the Arizona cohort, with 
81 samples per group, we have 100% power to detect differences of 2.5% between high and low 
Braak stage at a significance level of P < 3.85E-03.  
 
In the London cohort, with 113 samples, we have 80% power to detect r of 0.34 at a significance level 
of P < 3.85E-03 and 90% power to detect r of 0.38 at the same significance threshold. With 146 
samples in the Mount Sinai cohort, we have 80% power to detect r of 0.30 at a significance level of P 
< 3.85E-03 and 90% power to detect r of 0.33 to the same significance. For the ROSMAP cohort, with 
720 samples, we have 80% power to detect r of 0.14 at a significance level of P < 3.85E-03, and 90% 
power to detect r of 0.15 to the same significance. For the Arizona cohort, with 401 samples, we have 
80% power to detect r of 0.18 at a significance level of 3.85E-03 and 90% power to detect r of 0.21 to 
the same significance. 
 
Regarding APOE genotype, we have 100% power to detect differences of 2.5% between genotype 
groups at a significance level of P < 3.85E-03, in the London cohort, with 12 samples per group 
(number of samples with two E4 alleles), 99% power in the Mount Sinai cohort, with 5 samples per 
group (number of samples with two E4 alleles), we have 72% power, and 100% power in the 
ROSMAP cohort, with 9 samples per group (number of samples with two E4 alleles), and in the 
ROSMAP cohort, with 27 samples per group (number of samples with two E4 alleles). 
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3.1 Loci in APOE are differentially methylated in the cortex in donors with Alzheimer’s 
disease 
We were interested to investigate whether any of the 450K probes that mapped to the APOE gene 
(N=13 probes) displayed differential DNA methylation in the cortex (PFC or STG) in donors with AD, 
compared to elderly non-demented controls. To address this we performed individual linear 
regressions for the 13 APOE probes in all four AD EWAS dataset cohorts (see Table 2.1), in each 
individual tissue. Our models looked for an association of disease diagnosis with DNA methylation 
whilst controlling for the co-variates of age, sex and neuronal cell proportion. We used a nominal 
significance level of P<0.05 and a Bonferroni significance level of P<3.85E-03 (i.e. 0.05/13 tests). To 
identify probes showing a Bonferroni-significant difference in methylation in AD across all cohorts we 
conducted a Fisher’s meta-analysis to identify consistent effects  
 
When we examined the individual cohorts we identified a number of loci that were nominally 
significantly hypomethylated methylated in AD in the PFC (Table 3.1), but with only one loci 
exceeding Bonferroni significance in only one cohort (cg21879725 [London cohort: P = 6.88E-04) 
(Figure 3.1). However, we did identify a number of hypomethylated loci in AD in the STG that 
exceeded Bonferroni significance (cg16471933 [Arizona cohort: P = 3.79E-06], cg05501958 [Mount 
Sinai cohort: P = 6.23E-05; Arizona cohort: P = 1.14E-13], cg18799241 [Arizona cohort: P = 3.31E-
05], cg21879725 [Mount Sinai cohort: P = 4.02E-05; Arizona cohort: P = 6.71E-07]) (Figure 3.2).  
 
We were also interested to investigate whether similar patterns of methylation in disease were seen 
across the cohorts within tissues (regardless of significance). We observed that methylation patterns 
were not similar in the PFC (Figure 3.3), but showed similarity in the STG (Figure 3.4) 
 
A meta-analysis of all three PFC cohorts revealed seven nominally significant differentially methylated 
loci (Figure 3.5; Figure 3.6; Figure 3.8), with two loci that exceeded Bonferroni significance 
(cg05501958: P = 3.64E-03; cg21879725: P = 1.31E-03), whilst in the STG we identified five 
nominally significant differentially methylated loci (Figure 3.5; Figure 3.7; Figure 3.8), with four 
neighbouring loci reaching Bonferroni significance (cg16471933: P = 1.05E-05; cg05501958: P = 
1.67E-15; cg18799241: P = 3.26E-05; cg21879725: P = 7.85E-09) 
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Table 3.1 - Significant diagnosis-associated DMPs in the APOE gene in the prefrontal cortex (PFC) and superior temporal gyrus (STG) of AD 
subjects and non-demented controls (CTL).  
Shown for all of the 13 CG probes in the APOE gene are P values from a Fisher’s meta-analysis, percentage of DNA methylation, and 
associated P value derived from a linear regression analysis  adjusting for the covariates of age, gender and cell proportion, in each individual 
tissue in each individual cohort for CTL and AD subjects. All p-values reaching Bonferroni significance (<3.85E-03 ) are highlighted in bold. 
    London cohort Mount Sinai cohort Arizona cohort ROSMAP cohort 
  Fisher's test STG PFC STG PFC STG PFC 
Probe 
STG 
p value 
PFC 
p value 
p 
value 
CTL 
% 
met 
AD  
% 
met p value 
CTL 
% 
met 
AD 
% 
met p value 
CTL 
% 
met 
AD  
% 
met p value 
CTL 
% 
met  
AD  
% 
met p value 
CTL 
% 
met 
AD  
% 
met p value 
CTL 
% 
met 
AD  
% 
met 
cg14123992 5.71E-02 1.63E-02 0.27 54.30 55.87 4.51E-02 66.24 68.21 0.36 63.68 64.30 0.11 54.44 55.65 2.26E-02 59.45 60.24 0.39 56.62 56.32 
cg04406254 0.26 5.23E-02 0.14 57.36 59.07 7.47E-03 72.75 75.11 0.66 66.34 66.62 0.64 63.06 63.35 0.24 65.83 66.23 0.38 58.36 58.08 
cg01032398 0.64 0.31 0.32 83.06 83.84 0.35 86.36 86.78 0.41 80.34 80.62 0.35 81.49 81.18 0.91 84.49 84.51 0.27 82.98 83.23 
cg26190885 0.48 0.11 0.26 18.10 17.59 8.60E-02 17.02 16.36 0.57 16.38 16.53 0.10 17.59 17.13 0.44 22.18 22.36 0.54 80.47 81.36 
cg12049787 0.98 0.76 1.00 11.32 11.33 0.90 10.86 10.91 0.60 10.69 10.87 0.91 15.72 15.75 1.00 14.70 14.70 0.22 16.17 15.74 
cg08955609 0.80 0.86 0.43 6.13 6.24 0.36 6.26 6.04 0.64 7.28 7.18 0.77 7.43 7.48 0.77 6.38 6.41 0.49 9.16 9.07 
cg18768621 0.22 0.33 0.14 11.71 12.25 0.20 13.85 13.17 0.13 12.72 13.24 0.63 14.94 15.10 0.91 14.51 14.54 0.38 12.68 12.45 
cg19514613 0.18 0.16 0.87 13.65 13.68 6.91E-02 15.72 14.77 0.27 11.48 11.87 0.46 15.12 15.39 4.87E-02 16.08 16.65 0.58 21.01 21.18 
cg06750524 0.39 2.77E-02 0.91 42.38 42.65 2.45E-02 42.50 40.67 0.97 40.00 40.02 0.16 39.88 40.62 4.82E-02 45.86 46.43 0.58 54.47 54.74 
cg16471933 1.05E-05 9.14E-02 0.63 76.60 76.49 5.88E-02 75.29 76.95 2.85E-02 74.00 72.73 4.32E-03 70.44 68.67 
3.79E-
06 80.49 79.16 0.10 71.63 72.70 
cg05501958 1.67E-15 
3.64E-
03 0.26 82.98 82.42 0.32 86.28 87.23 
6.23E-
05 80.68 78.42 0.20 80.89 80.14 
1.14E-
13 85.44 83.16 3.00E-02 71.56 72.68 
cg18799241 3.26E-05 3.39E-03 0.39 84.05 83.45 7.73E-02 82.88 84.14 1.92E-02 82.25 81.22 0.30 79.72 79.27 
3.31E-
05 86.76 85.86 1.12E-02 83.11 84.19 
cg21879725 7.85E-09 
1.31E-
03 0.90 83.95 84.59 
6.88E-
04 83.23 86.64 
4.02E-
05 76.99 74.78 0.26 77.76 77.04 
6.71E-
07 86.98 85.56 2.28E-02 28.82 29.00 
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Figure 3.1 - A Manhattan plot of the APOE region, highlighting associations between DNA 
methylation and disease diagnosis in the PFC in three cohorts. 
 In our linear regression analyses, cg16471933 in the Mount Sinai cohort, and cg21879725 
in the Mount Sinai and ROSMAP cohorts exceeded the Bonferroni significance threshold 
(black line: P < 3.85E-03 ). The three PFC cohorts are denoted as different shapes. P value 
is shown on the X axis and genomic position on chromosome 19 is shown on the Y axis. 
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Figure 3.2 - A Manhattan plot of the APOE region, highlighting associations between DNA 
methylation and diagnosis in the STG in three cohorts.  
In our linear regression analyses, four CpG sites (cg16471933, cg05501958, cg18799241, 
cg21879725) passed our Bonferroni significance threshold (black line: P < 3.85E-03 ). The 
three STG cohorts are denoted as different shapes. P value is shown on the X axis and 
genomic position on chromosome 19 is shown on the Y axis. 
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Figure 3.3 - A Graph showing effect-size coefficient (methylation difference between control 
and AD samples) across the APOE gene in all three cohorts in the PFC samples.  
Adjusted beta value difference between AD and control are represented as methylation 
effect size. The different cohorts are denoted by different line colours. 
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Figure 3.4 - A Graph showing effect-size coefficient (methylation difference between control 
and AD samples) across the APOE gene in all three cohorts in the STG samples.  
Adjusted beta value difference between AD and control are represented as methylation 
effect size. The different cohorts are denoted by different line colours. 
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Figure 3.5  - A Manhattan plot of the APOE region, highlighting associations between DNA 
methylation and diagnosis in the STG and PFC in our meta-analysis.  
We identified four CpG sites (cg16471933, cg05501958, cg18799241, cg21879725) that 
passed the Bonferroni significance threshold (black line: P < 3.85E-03 ) in the STG, and one 
(cg21879725) in the PFC. The STG is shown in green and the PFC is shown in red. P value 
is shown on the X axis and genomic position on chromosome 19 is shown on the Y axis. 
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 Figure 3.6 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in AD (red) and CTL 
(pink) samples in the PFC.  
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = Nominal significance (P<0.05), *** = Bonferroni significance (P<3.85E-03)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in AD (dark green) 
andCTL (light green) samples in the STG.  
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = P<0.05, *** =P<3.85E-03 (uncorrected P values). 
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Figure 3.7 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in AD (green) and CTL 
(light green) samples in the STG.  
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = Nominal significance (P<0.05), *** = Bonferroni significance (P<3.85E-03). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in AD (dark colours) 
and CTL (light colours) samples in the PFC (red shades) and STG (green shades).  
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All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = Nominal significance (P<0.05_, *** = Bonferroni significance (P<3.85E-03)   
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3.2 Loci in APOE are differentially methylated with respect to Alzheimer’s disease 
neuropathology  
As we had identified disease-associated differentially methylated loci in APOE we were also 
interested to investigate whether we could identify any loci that were differentially methylated with 
respect to disease neuropathology measures. To address this we again performed individual linear 
regressions for the 13 APOE probes in all four AD EWAS dataset cohorts in each individual tissue, 
but looking for an association of Braak stage (as a measure of tau neuropathology) with DNA 
methylation whilst controlling for age, sex and neuronal cell proportion. We then performed a Fisher’s 
meta-analysis to identify consistent effects across cohorts. 
 
When we examined the individual cohorts we identified a number of hypomethylated loci with respect 
to Braak stage that reached nominal significance in the PFC and STG (Table 3.2). However, only one 
loci reached Bonferroni significance in the PFC (cg18799241 [ROS/MAP cohort: P = 3.08E-03]) 
(Figure 3.9), whilst in the STG four probes reached Bonferroni significance (cg16471933 [Arizona 
cohort: P = 1.76E-06], cg05501958 [Mount Sinai cohort: P = 7.33E-05; Arizona cohort: P = 1.36E-12], 
cg18799241 [Arizona cohort: P = 1.17E-03], cg21879725 [Mount Sinai cohort: P = 3.58E-05; Arizona 
cohort: P = 2.97E-06]) (Figure 3.10). Interestingly, these four probes were the four closest to the 5’ 
end of the gene. When we looked at the pattern of methylation difference between Braak 0 and Braak 
VI samples (i.e. effect size), we saw little similarity between cohorts in the PFC (Figure 3.11), but a 
very similar pattern between cohorts in the STG (Figure 3.12).  
 
The meta-analysis across all three PFC cohorts highlighted six nominally significant loci (Figure 3.13; 
Figure 3.14; Figure 3.16), with two Bonferroni significant loci (cg18799241: P = 2.56E-03; 
cg21879725: P = 3.15E-04), both at the 5’ end of the gene. In the meta-analysis of the STG we 
identified five nominally significant loci (Figure 3.13; Figure 3.15; Figure 3.16), with four of these loci 
being Bonferroni significant (cg16471933: P = 7.01E-07; cg05501958: P = 4.20E-14; cg18799241: P 
= 1.57E-03; cg21879725: P = 2.46E-08). A Forest plot highlighting the DNA methylation difference in 
disease in each cohort and tissue for these four loci can be found in Figure 3.17. 
 
Together, these results may indicate multi-regional differential methylation of the APOE gene in AD, 
particularly in the STG, which correlated with greater degrees of neuropathology and diagnosis.  
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Table 3.2 - Significant Braak-associated DMPs in the APOE gene in the prefrontal cortex (PFC) and superior temporal gyrus (STG).  
Shown for all of the 13 CG probes in the APOE gene are P values from a Fisher’s meta-analysis, percentage of DNA methylation in Braak 0 
and Braak VI individuals, and associated P value derived from a linear regression analysis  adjusting for the covariates of age, gender and cell 
proportion, in each individual tissue in each individual cohort. All p-values reaching Bonferroni significance (< 3.85E-03 ) are highlighted in bold. 
 
Fisher’s Test London cohort Mount Sinai cohort  Arizona cohort ROSMAP cohort 
  STG PFC STG PFC  STG PFC STG PFC 
Probe 
p  
value 
p  
value 
p 
value 
Braak 
0 % 
met 
Braak 
VI % 
met p value 
Braak 
0 % 
met 
Braak 
VI % 
met p value 
Braak 
0 % 
met 
Braak 
VI % 
met p value 
Braak 
0 % 
met 
Braak 
VI % 
met p value 
Braak 
0 % 
met 
Braak 
VI % 
met p value 
Braak 
0 % 
met 
Braak 
VI % 
met 
cg14123992 7.22E-03 4.92E-02 0.15 57.35 59.58 0.01 64.76 67.42 0.02 64.97 67.55 0.16 54.63 56.35 0.06 60.16 61.41 0.91 57.76 57.82 
cg04406254 0.10 0.10 0.04 61.46 63.43 5.63E-03 70.46 73.10 0.38 66.79 67.71 0.94 62.98 63.05 0.30 66.30 66.96 0.95 60.62 60.58 
cg01032398 0.34 4.11E-02 0.06 85.14 85.97 0.22 86.29 86.85 0.65 80.42 80.67 0.39 81.43 80.97 0.84 84.58 84.51 0.02 85.66 86.47 
cg26190885 0.74 0.08 0.18 17.16 16.39 0.04 17.43 16.60 0.98 16.37 16.38 0.28 17.57 17.07 0.96 22.46 22.49 0.37 25.86 26.27 
cg12049787 0.89 0.29 0.90 12.19 12.11 0.39 11.18 10.79 0.39 10.91 11.37 0.11 15.38 14.55 0.90 14.65 14.70 0.58 17.24 16.96 
cg08955609 0.87 0.87 0.53 6.72 6.83 0.63 6.48 6.36 0.69 7.23 7.09 0.80 7.38 7.30 0.78 6.48 6.43 0.57 8.60 8.47 
cg18768621 
0.35 0.48 0.47 11.66 11.93 0.17 13.38 12.63 0.15 13.06 13.84 0.61 14.98 15.26 0.51 14.14 14.48 0.61 13.40 13.21 
cg19514613 0.31 0.09 0.44 12.66 12.42 0.02 15.92 14.59 0.72 11.52 11.73 0.40 15.21 15.70 0.09 16.46 17.38 0.61 20.18 20.42 
cg06750524 0.31 0.12 0.29 42.05 43.06 0.02 43.26 41.08 0.94 39.96 39.91 0.82 39.53 39.34 0.11 46.25 47.13 0.45 55.46 55.98 
cg16471933 
7.01E-
07 4.08E-03 0.27 76.85 75.24 0.32 74.07 75.08 7.08E-03 72.87 70.36 4.35E-03 70.01 67.14 
1.76E-
06 79.58 76.97 0.13 71.26 72.69 
cg05501958 
4.20E-
14 8.45E-03 0.57 83.32 81.99 0.29 83.06 84.09 
7.33E-
05 79.13 75.53 8.28E-03 80.21 77.70 
1.36E-
12 83.64 79.50 0.03 71.12 72.83 
cg18799241 
1.57E-
03 
2.56E-
03 0.67 84.37 83.59 0.03 81.86 83.55 0.03 81.59 80.06 0.44 79.68 79.14 
1.17E-
03 85.72 84.38 
3.08E-
03 83.62 85.37 
cg21879725 
2.46E-
08 
3.15E-
04 0.79 85.39 84.97 7.89E-03 80.79 83.68 
3.58E-
05 75.44 71.87 0.04 77.19 75.00 
2.97E-
06 85.76 83.24 0.01 80.58 82.05 
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Figure 3.9 - A Manhattan plot of the APOE region, highlighting associations between DNA 
methylation and Braak stage in the PFC in three cohorts.  
In our linear regression analyses, cg18799241 in the ROSMAP cohort exceeded the 
Bonferroni significance threshold (black line: P < 3.85E-03 ). The three PFC cohorts are 
denoted as different shapes. P value is shown on the X axis and genomic position on 
chromosome 19 is shown on the Y axis. 
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Figure 3.10 - A Manhattan plot of the APOE region, highlighting associations between DNA 
methylation and Braak stage in the STG in three cohorts.  
In our linear regression analyses, four CpG sites (cg16471933, cg05501958, cg18799241, 
cg21879725) passed our Bonferroni significance threshold (black line: P < 3.85E-03 ) in the 
Arizona cohort, with two of these (cg05501958 and cg21879725) also reaching Bonferroni 
significance in the Mount Sinai cohort. The three STG cohorts are denoted as different 
shapes. P value is shown on the X axis and genomic position on chromosome 19 is shown 
on the Y axis. 
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Figure 3.11 - A graph showing effect-size coefficient (methylation difference between Braak 
0 and Braak VI samples) across the APOE gene in all three cohorts in the PFC samples.  
Adjusted beta value difference between Braak 0 and Braak VI are represented as 
methylation effect size. The different cohorts are denoted by different line colours. 
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Figure 3.12 - A graph showing effect-size coefficient (methylation difference between Braak 
0 and Braak VI samples) across the APOE gene in all three cohorts in the STG samples. 
Adjusted beta value difference between Braak 0 and Braak VI are represented as 
methylation effect size. The different cohorts are denoted by different line colours. 
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Figure 3.13 - A Manhattan plot of the APOE region, highlighting associations between DNA 
methylation and Braak stage in the STG and PFC in our meta-analysis.  
We identified four CpG sites (cg16471933, cg05501958, cg18799241, cg21879725) that 
passed the Bonferroni significance threshold (black line: P <3.85E-03 ) in the STG, and two 
(cg18799241 and cg21879725) in the PFC. The STG is shown in green and the PFC is 
shown in red. P value is shown on the X axis and genomic position on chromosome 19 is 
shown on the Y axis. 
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Figure 3.14 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in Braak 0 (red) and 
Braak VI (pink) samples in the PFC.  
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = Nominal significance (P < 0.05), *** = Bonferroni significance (P < 3.85E-03)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in Braak VI (red) and 
Braak 0 (pink) samples in the STG. All CpG loci are ordered according to genomic position.  
Box and whisker plots show median, upper and lower quartiles, and maximum and minimum values, with outliers included. Key: * = P < 0.05,  
*** =P < 3.85E-03 (uncorrected P values).  
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Figure 3.15 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in Braak VI (light 
green) and Braak 0 (dark green) samples in the STG.  
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = Nominal significance (P < 0.05), *** = Bonferroni significance (P < 3.85E-03). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in Braak VI (dark 
colours) and Braak 0 (light colours) samples in the PFC (red shades) and STG (green shades).  
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = P < 0.05, *** =P < 3.85E-03 (uncorrected P values).  
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Figure 3.16 - A box and whisker plot demonstrating average corrected DNA methylation levels for the 13 CpGs in APOE in Braak 0 (dark 
colours) and Braak VI (light colours) samples in the PFC (red shades) and STG (green shades). 
All CpG loci are ordered according to genomic position. Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values, with outliers included. Key: * = Nominal significance ( P < 0.05), *** = Bonferroni significance (P < 3.85E-03). 
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Figure 3.17- Forest plots highlighting the effect size of cg1647933, cg05501958, 
cg18799241 and cg21879725 across all cohorts and tissues. 
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3.3 APOE shows hypomethylation with advancing age in AD in the STG 
As APOE is the strongest common genetic risk factor for late-onset AD, we were interested to 
investigate whether we observed a mQTL in our data, whereby the number of APOE ε4 alleles altered 
DNA methylation within the gene. We were also interested to investigate whether this association 
differed with age, given that AD is a disease of the elderly. To address this we looked for an 
association of (a) age, (b) APOE genotype (number of ε4 alleles) and (c) an interaction between age 
and genotype with DNA methylation in our meta-analysis cohort, regardless of disease (Table 3.3). 
We saw that in the PFC cg26190885, cg19514613 and cg06750524 showed a Bonferroni significant 
decrease in DNA methylation with advancing age (P = 7.02E-05, P = 1.01E-03, P = 2.98E-05, 
respectively). None of the probes showed any association with APOE genotype (Table 3.3), in either 
the PFC (Figure 3.18) or STG (Figure 3.19).  
 
When we stratified the data by AD diagnosis, we saw no Bonferroni-significant association of (a) age, 
(b) the number of APOE ε4 alleles or (c) an interaction of age and genotype on DNA methylation 
levels for the 13 probes in the PFC for either AD or control samples (Table 3.4). However, we did see 
a Bonferroni-significant association of DNA methylation of age (but not genotype nor an interaction 
between the two variables) in the STG for AD, but not control samples (Table 3.5) at cg14123992, 
cg04406254, cg01032398  and cg06750524 (P = 3.84E-04, P = 1.21E-03, P = 4.54E-04, P = 1.40E-
04, respectively). This may indicate that the decrease in DNA methylation at these four loci in APOE 
with age is only observed in AD subjects. Interestingly, three of these loci (cg14123992, cg04406254 
and cg01032398) are all at the 5’ end of the gene, located 1500bp from the transcription start site 
(TSS). 
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Table 3.3 - Association of DNA methylation in the APOE gene with (a) age, (b) the number of APOE ε4 alleles and (c) and the interaction 
between genotype and age in all samples used in the AD meta-analysis (regardless of diagnosis) in the PFC and STG.  
Shown for all 13 probes are the effect size (difference in DNA methylation per unit of variable), and associated P value. All P values reaching 
Bonferroni significance (<3.85E-03) are highlighted in bold. Probes are ordered by genomic position. 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
PFC STG 
Age Genotype Age*Genotype Age Genotype Age*Genotype 
Estimate P value Estimate P value Estimate P value Estimate P value Estimate P value Estimate P value 
cg14123992 -1.37E-03 3.97E-03 9.98E-03 0.84 2.31E-06 1.00 -9.05E-04 4.30E-03 -3.10E-02 0.32 6.50E-04 8.30E-02 
cg04406254 -1.26E-03 9.38E-03 6.29E-02 0.21 -6.89E-04 0.23 -1.02E-03 
2.73E-
03 -5.82E-02 8.23E-02 9.46E-04 1.93E-02 
cg01032398 -7.83E-04 2.04E-02 2.12E-02 0.54 -2.81E-04 0.49 -4.09E-04 3.20E-02 -1.33E-02 0.48 2.27E-04 0.31 
cg26190885 -1.20E-03 
7.02E-
05 -4.63E-02 0.13 4.78E-04 0.18 -1.64E-04 0.33 -8.92E-03 0.59 1.05E-04 0.60 
cg12049787 -7.20E-04 3.02E-02 -4.10E-02 0.23 4.34E-04 0.27 -1.22E-04 0.46 1.03E-02 0.52 -1.30E-04 0.50 
cg08955609 -1.59E-04 0.23 -2.79E-02 3.94E-02 3.01E-04 5.49E-02 1.26E-04 9.61E-02 1.29E-02 8.37E-02 -1.60E-04 7.59E-02 
cg18768621 4.60E-05 0.853379 1.04E-03 0.97 -1.92E-05 0.95 1.65E-04 0.34 8.15E-03 0.63 -1.26E-04 0.54 
cg19514613 -1.14E-03 
1.01E-
03 -2.32E-02 0.51 2.20E-04 0.59 -2.63E-04 0.18 7.63E-03 0.69 -6.47E-05 0.78 
cg06750524 -2.40E-03 
2.98E-
05 -7.16E-02 0.22 7.85E-04 0.25 -5.92E-04 2.95E-02 1.45E-02 0.59 -7.15E-05 0.82 
cg16471933 2.13E-04 0.75 8.62E-02 0.21 -1.05E-03 0.19 -6.03E-04 0.10 -4.97E-02 0.16 6.24E-04 0.15 
cg05501958 1.27E-03 1.80E-02 1.15E-01 3.74E-02 -1.44E-03 2.48E-02 -4.57E-05 0.85 -2.29E-02 0.32 1.36E-04 0.62 
cg18799241 -5.28E-04 0.24 -1.67E-02 0.72 1.70E-04 0.75 -4.55E-04 8.20E-02 -2.22E-02 0.39 3.02E-04 0.33 
cg21879725 -6.55E-04 0.27 4.06E-02 0.51 -6.41E-04 0.37 -4.60E-04 0.20 -3.24E-02 0.36 4.14E-04 0.34 
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Figure 3.18 - Probes within APOE show no association with APOE ε4 genotype in the PFC in the combined AD and control cohorts.  
Probes are in order of genomic position. Probes are in order of genomic position. Box and whisker plot shows median, upper and lower 
quartiles, and maximum and minimum values, with outliers included. Blue represents zero ε4 alleles (N = 660), red represents one ε4 allele (N 
= 266) and green represents two ε4 alleles (N = 26).Zero APOE ε4 alleles n = 660, one APOE ε4 alleles n = 266, two ε4 alleles n = 26. 
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Figure 3.19 - Probes within APOE show no association with APOE ε4 genotype in the STG in the combined AD and control cohorts.  
Probes are in order of genomic position. Box and whisker plot shows median, upper and lower quartiles, and maximum and minimum values, 
with outliers included. Blue represents zero ε4 alleles (N = 360), red represents one ε4 allele (N = 220) and green represents two ε4 alleles (N = 
44).  
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Table 3.4 - Association of DNA methylation in the APOE gene with (a) age, (b) the number of APOE ε4 alleles and (c) and the interaction 
between genotype and age in AD and control samples independently in the PFC.  
Shown for all 13 probes are the effect size (difference in DNA methylation per unit of variable), and associated P value. No probes reached 
Bonferroni significance 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
CONTROL AD 
Age Genotype Age*Genotype Age Genotype Age*Genotype 
Estimate P value Estimate P value Estimate P value Estimate P value Estimate P value Estimate P value 
cg14123992 
2.95E-04 0.66 -3.26E-03 0.98 3.20E-04 0.87 -1.47E-03 2.37E-02 9.74E-04 0.99 1.23E-04 0.85 
cg04406254 
9.52E-04 0.13 8.54E-02 0.57 -9.82E-04 0.58 -1.26E-03 0.06 6.60E-02 0.27 -6.96E-04 0.31 
cg01032398 
3.44E-04 0.44 -2.47E-02 0.82 3.47E-04 0.79 -9.02E-04 0.05 1.71E-02 0.68 -2.25E-04 0.64 
cg26190885 
-7.88E-04 0.15 -1.62E-01 0.22 1.87E-03 0.23 -1.11E-03 6.85E-03 -3.47E-02 0.34 3.50E-04 0.40 
cg12049787 
-8.11E-05 0.91 -4.80E-02 0.77 5.87E-04 0.77 -7.02E-04 0.11 -3.61E-02 0.36 3.84E-04 0.40 
cg08955609 
-2.42E-05 0.92 -5.21E-02 0.36 5.62E-04 0.40 -1.44E-04 0.42 -2.68E-02 0.10 2.92E-04 0.11 
cg18768621 
1.12E-03 0.07 1.92E-01 0.20 -2.40E-03 0.18 -1.36E-04 0.67 -1.62E-02 0.57 1.91E-04 0.56 
cg19514613 
-1.25E-04 0.84 1.94E-01 0.20 -2.34E-03 0.19 -9.89E-04 3.44E-02 -1.85E-02 0.66 1.85E-04 0.70 
cg06750524 
-8.76E-04 0.35 -2.23E-02 0.92 -2.96E-05 0.99 -2.02E-03 9.08E-03 -4.65E-02 0.50 5.46E-04 0.49 
cg16471933 
-1.26E-05 0.99 3.16E-01 0.39 -3.91E-03 0.37 -4.56E-04 0.59 4.79E-02 0.53 -6.33E-04 0.47 
cg05501958 
-3.45E-04 0.76 1.26E-01 0.64 -1.74E-03 0.58 4.08E-04 0.55 6.37E-02 0.31 -9.01E-04 0.21 
cg18799241 
6.86E-04 0.57 1.43E-02 0.96 -3.68E-04 0.92 -1.42E-03 1.09E-02 -6.43E-02 0.20 6.97E-04 0.22 
cg21879725 
-2.57E-04 0.75 1.30E-01 0.50 -1.78E-03 0.44 -7.73E-04 0.34 3.90E-02 0.60 -6.17E-04 0.46 
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Table 3.5 - Association of DNA methylation in the APOE gene with (a) age, (b) the number of APOE ε4 alleles and (c) and the interaction 
between genotype and age in AD and control samples independently in the STG.  
Shown for all 13 probes are the effect size (difference in DNA methylation per unit of variable), and associated P value. All P values reaching 
Bonferroni significance (<3.85E-03) are highlighted in bold. Probes are ordered by genomic position. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONTROL AD 
Age Genotype Age*Genotype Age Genotype Age*Genotype 
Estimate P value Estimate P value Estimate P value Estimate P value Estimate P value Estimate P value 
cg14123992 
-4.45E-04 0.34 -8.12E-02 0.13 1.25E-03 7.05E-02 -1.60E-03 3.84E-
04 
-3.62E-02 0.37 6.76E-04 0.16 
cg04406254 
-7.80E-04 0.12 -1.18E-01 4.36E-02 1.65E-03 2.79E-02 -1.57E-03 1.21E-
03 
-5.63E-02 0.20 8.82E-04 9.11E-02 
cg01032398 
-1.26E-04 0.67 -1.35E-03 0.97 1.17E-05 0.98 -9.23E-04 4.54E-
04 
-3.66E-02 0.13 4.70E-04 9.60E-02 
cg26190885 
1.87E-04 0.48 5.18E-03 0.86 -1.09E-04 0.78 -5.81E-04 1.37E-02 -2.72E-02 0.20 3.08E-04 0.22 
cg12049787 
1.74E-04 0.47 -5.37E-03 0.85 4.04E-05 0.91 -4.97E-04 3.19E-02 4.35E-03 0.84 -7.49E-05 0.76 
cg08955609 
1.33E-04 0.26 -8.56E-04 0.95 2.05E-05 0.91 2.01E-04 5.49E-02 2.30E-02 1.64E-02 -2.69E-04 1.78E-02 
cg18768621 
-1.31E-04 0.65 -2.99E-02 0.37 4.31E-04 0.32 1.73E-04 0.45 1.07E-02 0.61 -1.94E-04 0.44 
cg19514613 
-3.36E-04 0.29 -1.94E-02 0.60 2.79E-04 0.56 -5.26E-04 4.09E-02 1.56E-03 0.95 -3.63E-05 0.90 
cg06750524 
-8.76E-05 0.82 1.78E-02 0.69 -1.04E-04 0.86 -1.48E-03 1.40E-
04 
-2.77E-02 0.43 3.63E-04 0.38 
cg16471933 
5.51E-05 0.92 -5.71E-03 0.93 -3.36E-05 0.97 -1.24E-03 1.51E-02 -8.13E-02 8.15E-02 9.92E-04 7.25E-02 
cg05501958 
5.99E-05 0.87 -2.47E-02 0.55 1.25E-04 0.81 2.34E-04 0.47 -8.52E-05 1.00 -8.16E-05 0.82 
cg18799241 
7.23E-05 0.85 -8.38E-03 0.85 8.97E-05 0.87 -1.00E-03 7.85E-03 -4.35E-02 0.20 5.44E-04 0.18 
cg21879725 
8.88E-05 0.88 -3.46E-02 0.60 4.08E-04 0.63 -9.85E-04 5.16E-02 -4.62E-02 0.32 5.72E-04 0.29 
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3.4 The 5’ end of the APOE gene shows a cis mQTL in post-natal PFC tissue 
Next, we were interested to investigate whether there was an association of APOE DNA methylation 
with age or APOE genotype in a larger cohort of post-natal PFC samples collected by our group. To 
this end we extracted DNA methylation from the “big brain dataset” (see section 2.1.2), which 
included EWAS data from MCI, ASD, schizophrenia, depression and age-matched controls for 12 
APOE probes that passed QC. We added this data to the AD and control data we had been analysing 
in section 3.3 and looked for an association of DNA methylation individually at each probe with (a) 
age, (b) the number of APOE ε4 alleles and (c) an interaction of age and genotype, whilst controlling 
for sex, cell proportion, brain region and brain bank (Table 3.6). In this larger cohort we observed 
Bonferroni significant hypermethylation of cg16471933 with advancing age (P = 3.89E-03) (Figure 
3.20). We also observed a Bonferroni significant mQTL at cg14123992 (Figure 3.21: P = 2.53E-06) 
and cg04406254 (Figure 3.22: P = 8.23E-05), with increased DNA methylation with increased 
numbers of APOE ε4 alleles. Both of these two probes are located at the 5’ end of the gene, within 
1500bp of the TSS. 
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Table 3.6 - Association of DNA methylation in the APOE gene with (a) age, (b) the number 
of APOE ε4 alleles and (c) and the interaction between genotype and age in post-natal 
tissue.  
Shown for all of 12 probes with data available are the effect size (difference in DNA 
methylation per unit of variable), and associated P value. All p-values reaching Bonferroni 
significance (<4.17E-03) are highlighted in bold. Probes are ordered by genomic position. 
 
 
Probe 
Age Number of APOE ε4 alleles Interaction (Age x No. alleles) 
Effect Size P value Effect Size P value Effect Size P value 
cg14123992 -1.90E-04 2.65E-02 3.23E-02 2.53E-06 -1.58E-04 6.49E-02 
cg04406254 -1.68E-04 2.88E-02 2.42E-02 8.23E-05 -1.07E-04 0.16 
cg01032398 -7.75E-05 0.13 7.67E-03 6.18E-02 -6.39E-05 0.21 
cg26190885 -1.38E-05 0.79 2.16E-03 0.60 -4.57E-05 0.37 
cg12049787 -1.02E-04 6.36E-02 3.94E-03 0.37 -5.84E-05 0.29 
cg08955609 -2.44E-05 0.36 4.62E-03 2.87E-02 -5.23E-05 4.78E-02 
cg18768621 - - - - - - 
cg19514613 -4.97E-05 0.39 6.62E-03 0.15 -7.51E-05 0.20 
cg06750524 -9.37E-05 0.27 1.55E-02 2.10E-02 -1.25E-04 0.14 
cg16471933 2.88E-04 3.89E-03 1.42E-02 7.38E-02 -1.94E-04 5.12E-02 
cg05501958 -9.42E-05 0.33 1.88E-03 0.81 -1.23E-04 0.20 
cg18799241 1.07E-04 0.13 1.43E-02 1.17E-02 -1.56E-04 2.81E-02 
cg21879725 1.41E-04 0.10 1.67E-02 1.64E-02 -2.11E-04 1.54E-02 
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Figure 3.20 - Cg16471933 shows a Bonferroni-significant association of DNA methylation 
with increasing age in post-natal PFC brain samples.  
Shown are adjusted beta values (corrected for sex, cell proportion, brain region and brain 
bank) in individual samples plotted against age (in years). Samples with zero APOE ε4 
alleles are shown in black, samples with one APOE ε4 allele are shown in red, and samples 
with two APOE ε4 alleles are shown in green.  
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Figure 3.21 - DNA methylation at cg14123992 shows an mQTL with respect to the number of APOE ε4 alleles in post-natal PFC samples, 
which is evident across all phenotypes.  
Box and whisker plot shows median, upper and lower quartiles, and maximum and minimum values, with outliers included. Blue represents 
zero ε4 alleles, red represents one ε4 alleles and green represents two ε4 alleles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 - DNA methylation at cg04406254 shows an mQTL with respect to the number of APOE ε4 alleles in post-natal PFC samples, 
which is evident across all phenotypes.  
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Box and whisker plot shows median, upper and lower quartiles, and maximum and minimum values, with outliers included. Blue represents 
zero ε4 alleles, red represents one ε4 alleles and green represents two ε4 alleles. 
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3.5 The 3’ end of the APOE gene shows hypomethylation during development  
Finally, we investigated whether loci in the APOE gene show altered DNA methylation with respect to 
age, or the number of APOE ε4 alleles in a unique cohort of pre-natal brain samples for which we 
have access to EWAS and APOE genotype data (Table 3.7). We observed a Bonferroni-significant 
association of decreased DNA methylation with increasing foetal age for cg21879725 (Figure 3.23: P 
= 8.13E-05). Interestingly, this was one of the loci where we had observed AD-associated 
hypomethylation in the STG and PFC in our meta-analysis. However, it is worth noting that only three 
donors were homozygous for APOE ε4, and therefore further analysis is required to validate this in a 
cohort with larger numbers of these individuals. 
  
Table 3.7 - Association of DNA methylation in the APOE gene with (a) age, (b) the number 
of APOE ε4 alleles and (c) and the interaction between genotype and age in pre-natal tissue.  
Shown for all of 12 probes with data available are the effect size (difference in DNA 
methylation per unit of variable), and associated P value. All p-values reaching Bonferroni 
significance (<4.17E-03) are highlighted in bold. Probes are ordered by genomic position. 
 
Probe 
Age Number of APOE ε4 alleles Interaction (Age x No. alleles) 
Effect Size P value Effect Size P value Effect Size P value 
cg14123992 0.037 0.53 -0.007 0.79 -0.048 0.66 
cg04406254 0.016 0.81 -0.018 0.56 -0.068 0.56 
cg01032398 -0.095 0.11 0.035 0.20 0.135 0.21 
cg26190885 0.080 0.10 0.000 0.99 -0.022 0.80 
cg12049787 0.021 0.55 -0.030 7.42E-02 -0.119 6.77E-02 
cg08955609 0.020 0.62 0.012 0.50 0.041 0.57 
cg18768621 - - - - - - 
cg19514613 0.058 0.20 -0.039 6.62E-02 -0.143 8.31E-02 
cg06750524 0.053 0.46 0.037 0.27 0.120 0.36 
cg16471933 -0.019 0.85 -0.027 0.57 -0.119 0.52 
cg05501958 -0.047 0.31 0.022 0.31 0.077 0.36 
cg18799241 -0.024 0.69 -0.024 0.39 -0.105 0.34 
cg21879725 -0.257 8.13E-05 0.082 6.82E-03 0.332 4.65E-03 
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Figure 3.23 - Cg21879725 shows a Bonferroni-significant association of DNA methylation 
with increasing age in pre-natal PFC brain samples.  
Shown are adjusted beta values (corrected for sex, cell proportion, brain region and brain 
bank) in individual samples plotted against the number of days post conception. Samples 
with zero APOE ε4 alleles are shown in blue, samples with one APOE ε4 allele are shown in 
red, and samples with two APOE ε4 alleles are shown in green. 
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CHAPTER 4 :  DISCUSSION 
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4.1 CpGs in the 3’ exon of APOE gene are differentially methylated with respect to AD 
diagnosis and pathology 
This study represents the first large-scale longitudinal study of APOE DNA methylation with respect to 
AD diagnosis, AD pathology, age and APOE genotype. The areas of the brain we studied, the STG 
and PFC, are involved in emotional perception and executive functions/ recall of short-term memory 
after encoding by the hippocampus respectively.  
 
Of the 13 CpG sites studied, four (cg16471933, cg05501958, cg18799241, cg21879725) were 
discovered to have Bonferroni-significant differential methylation (hypomethylation) within the STG 
with respect to AD diagnosis and Braak stage. cg18799241 also showed Bonferroni-significant 
differential methylation in the PFC with respect to Braak stage, along with  cg21879725. Furthermore, 
the latter probe was differentially methylated in the PFC with respect to diagnosis, alongside 
cg05501958. The fact we saw two loci that were differentially methylated in both brain regions 
potentially indicates common epigenetic dysfunction in the APOE gene in AD across different areas of 
the brain. Interestingly, all of these four differentially methylated sites were located in a well-defined 
CGI towards the 3’ untranslated region (UTR) of the APOE gene in the 4th exon spanning 880 base 
pairs, and were closely grouped within ~100 bases of each other. A previous study has grouped the 
13 CpG probes within APOE via their methylation levels and location into three distinct regions (Ma et 
al., 2015). In that study they classed these four CpG probes at the 3’ end of the gene as “Group 3” 
reporting they are in general hypermethylated across all tissues studied (>50% methylation). The 
other two regions they identified included “Group 1” located in the promoter and consisting of three 
probes (cg14123992, cg04406254, cg01032398) that are hypermethylated (>50% methylation) in all 
tissues studied) and “Group 2” consisting of the remaining six probes (cg26190885, cg12049787, 
cg08955609, cg18768621, cg19514613, cg06750524) that are found in the 5’ end of the gene and 
are generally hypomethylated (<50% methylation) in all tissues studied. The particular CGI in the 3’ 
UTR containing the “Group 3” probes where we identified AD-associated hypermethylation has been 
previously recognized as an important DMR in a previous cross-tissue study of the AD (Foraker et al., 
2015). The authors of that study showed that this CGI is differentially methylated in post-mortem brain 
tissue in a tissue-specific manner, with the highest levels of methylation in the cerebellum compared 
to the hippocampus and the lowest levels in the frontal lobe. However, in AD they only observed 
disease-associated differences (hypomethylation) in the hippocampus and frontal lobe, replicating the 
same direction of effect that we have seen in the temporal and frontal lobe in our study (Foraker et al., 
2015). The replication of their finding highlights the robustness of the results, as they used another 
technology (bisulfite pyrosequencing) and were limited to only 15 AD and 10 control subjects. Tulloch 
and colleagues recently assessed DNA methylation of the APOE gene in 15 AD and 14 control brain 
samples by performing bisulfite pyrosequencing in bulk (frontal lobe) tissue and fluorescence-
activated cell sorting (FACS) isolated neuronal and non-neuronal (glia) cells (Tulloch, Leong, 
Thomson, et al., 2018). They showed that hypomethylation of the CGI was observed in AD in glia, but 
not in neurons; as glia clear neural waste such as protein aggregations as part of their function, this 
may indicate the methylation of APOE plays a critical role in mediating this process.  
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Our data suggests differential methylation of the APOE 3’UTR CGI in AD brain in a tissue-specific 
manner, with a greater effect size (and more significant P values) in the STG than the PFC. The STG 
is a structure of the temporal lobe, which includes and is closely associated with the hippocampus 
(and its main information input, the entorhinal cortex (EC)) as a key processor of audiovisual sensory 
information to be encoded as long-term declarative memory; it has been previously found that AD 
pathology strikes first in the entorhinal cortex, before spreading to other cortices and the hippocampus 
(Devanand et al., 2012) (Huijbers et al., 2014) (Khan et al., 2014). . Interestingly, the 3’ UTR of genes 
is thought to be important in mediating the post-transcriptional processing of proteins. This is because 
the 3’ UTR can possess a variety of cis-acting regulatory elements that act as binding sites for trans-
acting elements such as RNA-binding proteins or RNAs themselves, which can mediate gene 
expression via alternative splicing (Matoulkova et al., 2012). This may imply that the differential 
methylation we observed in this region of the APOE gene may affect the post-transcriptional 
processing and regulation of the APOE protein. However, it is worth considering that the difference in 
DNA methylation in the current study is very small (average of 1.11% and 1.02% difference in STG 
and PFC for AD pathology, respectively).It is therefore worth considering whether these are 
functionally or biologically relevant. At many of the loci where I observed a Bonferroni-significant 
methylation difference in disease this was equivalent to ~1% increase in disease compared to control, 
which represents that ~1% of cells that were unmethylated have now become fully methylated at this 
CpG. Although this is unlikely to have considerable functional relevance this does require further 
exploration as we saw the same pattern across multiple adjacent CpGs in many different cohorts and 
tissues. Indeed, it will be of interest in the future to utilise epigenetic editing techniques to alter DNA 
methylation in APOE at these CpG sites and to examine the downstream consequences on cell 
function, particularly in the presence of Aβ. . 
 
A recent study of the 13 APOE CpG sites using Illumina 450 cell methylation data from various cell 
types obtained from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) and the 
Encyclopedia of DNA Elements consortium, indicates that DNA methylation is mostly positively 
correlated with APOE expression in three of the four CpG sites in the 3’UTR CG (Ma et al., 2015). 
This, taken together with our results suggest that methylation of these CpGs are critical to an overall 
shift towards increased APOE gene expression in AD, and possible cis-mediation of the 5’ TSS of the 
CGI by a 3’ DMR as a transcriptional enhancer. APOE transcriptional upregulation has also been 
demonstrated to be positively correlated with worse cognitive performance, increased expression of 
AD biomarkers, and accelerated Aβ aggregation and proteinopathy (K Gottschalk and Mihovilovic, 
2016). However, contradictory studies showed accelerated breakdown of Aβ with enhanced 
expression of APOE (Jiang et al., 2008), which may provide a strong argument for the impairment of 
APOE function via methylation-induced post-transcriptional processing. Conversely, there is evidence 
both for (Shi et al., 2017) and against (Morris et al., 2010) APOE exacerbating the development of 
Tau pathology, which may indicate the correlation with differential methylation found in this study may 
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not signify a direct causal link and further research is needed in to the downstream consequences of 
altering methylation of the 3’ UTR CGI of APOE.  
 
The two SNPs that confer APOE genotype (rs429358 and rs7412), which are two of the largest 
genetic risk factors for LOAD, are located between cg05501958 and cg18799241 within the 3’ UTR 
CGI. Interestingly, although we observed Bonferroni-significant AD diagnosis and Braak pathology-
associated hypermethylation at both these loci in the STG, and Braak pathology-associated 
hypermethylation at cg18799241 in the PFC, we did not observe any mQTL in this region in the AD 
and control samples. This suggests that the association of APOE genotype and epigenotype 
(hypomethylation) with AD are potentially via independent mechanisms. Concerning the influence of 
genotype, previous mQTL analyses seemed to show genotype only impacted methylation in the 3’ 
CGI in AD when comparing ε3/ε4 versus ε4/ε4 (Foraker et al., 2015). Together with our results, this 
implies the ε4 allele interacts with AD when epigenetically mediating APOE. A recent study used the 
ROS/MAP data to investigate whether methylation differences in the APOE region are related to 
APOE ε4 genotype and AD neuropathological (neuritic plaque) burden (Chibnik et al., 2015). They 
showed that there are large DNA methylation differences that are associated with genotype, but these 
do not seem to mediate the effect of genotype on outcome measures (Chibnik et al., 2015). In this 
study they did highlight that one CpG in the 3’ UTR CGI (cg18799241) shows increased levels of 
methylation with greater neuritic plaque burden, but is independent of APOE ε4. The authors suggest 
that non-genetic factors may influence AD pathology through differences in DNA methylation, which 
could lead to different gene expression. 
 
4.2 APOE DNA methylation differs with age in AD samples 
In the AD samples we observed a Bonferroni-significant association in the STG of decreased DNA 
methylation with advancing age for the three “Group 1” CpG probes, located in the promoter 
(cg14123992, cg04406254, cg01032398) as well as the “Group 2” probe cg06750524. This 
association was not observed in the PFC or in the control samples. One possible explanation for this 
association in the AD samples only could be because these individuals are more likely to have an 
APOE ε4 allele than control individuals. However, we did not observe any interaction of age with 
APOE genotype on DNA methylation at these CpG sites, nor did we see any effect of APOE genotype 
on DNA methylation at these CpG sites in the post-natal samples, which includes individuals with the 
genotype, but have not developed disease. It is therefore possible that hypomethylation of these four 
probes in the AD samples with advancing age may be driven by other disease mechanisms such as, 
for example, pathology in the STG specifically, and warrants further investigation. 
 
4.3 DNA methylation at the 5’ end of the APOE gene is driven by a mQTL in post-natal 
PFC samples 
Our study determined that two probes (cg14123992 and cg04406254), which are “Group 1” probes, 
situated at the 5’ end of the APOE gene near the TSS show differential methylation with respect to 
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APOE genotype in post-natal brain PFC brain samples. At both of these two loci, increased DNA 
methylation was observed with increasing numbers of APOE ε4 alleles. Interestingly, although APOE 
genotype is associated with AD diagnosis, we did not observe any AD-associated differential DNA 
methylation in this 5’ region. It is intriguing that we did not observe any mQTLs in the control/AD 
cohort, or the pre-natal samples which is most likely due to power, given the smaller sample sizes in 
those analyses, and may also have been affected by the greater distribution of APOE ε4 homozygous 
genotypes in our post-natal cohorts. These may also have generated observed genotype frequencies 
differing from Hardy-Weinberg expected APOE genotype frequencies for the general population, for 
example the Arizona and Mount Sinai cohorts had a different distribution of APOE genotypes 
compared to the general population, although this was not the case for the London or ROSMAP 
cohorts In the case of the pre-natal samples it may also suggest a tissue-specific effect, given that 
that analysis used bulk cortical tissue, whilst our post-natal analyses used PFC. A previous study has 
shown that cg14123992 shows a tissue-specific mQTL; Smith and colleagues highlighted a significant 
mQTL in the frontal cortex, temporal cortex and pons, which was not observed in the cerebellum or 
peripheral blood samples (Smith et al., 2014). Given that the two sites we identified as having a 
mQTL in post-natal samples are located at the 5’ end of the gene, close to the TSS, this may suggest 
that they could be cis-factors influencing transcription and further research should be undertaken to 
link the genetic and epigenetic differences we have identified to differences in APOE gene 
expression. These two CpG sites we identified are also located closely to another SNP (rs405509). 
This SNP is located at the 5’ end of the APOE gene within the promoter and possession of the T 
allele is reported to modulate the effect of APOE ε4 genotype on cognitive performance and brain 
grey matter structure (Ma et al., 2016). In addition it has been shown to alter the methylation of the 
nearby 5’ CpG cg04406254 as well as cg06750524 and cg16471933 located further towards the 3’ 
end of the gene (Ma et al., 2015). The same study also found a significant correlation between 
cg04406254 methylation and age. There may thus be a possible cooperative effect in epigenetic 
mediation of gene expression, and AD pathology by extension that is worsened with age, which is 
supported by prior observations of rs405509 interacting with APOE ε4 to impair cognition/neural 
functional connectivity in non-demented seniors (Ma et al., 2016). In the future it will be of interest to 
assess the relationship between rs05509 genotype and APOE methylation in the context of AD.  
 
Further evidence of negative effects of APOE DNA methylation on cognition, include an inverse 
association noted between methylation of the Group 1 CpGs at the 5’ promoter (cg04406254, 
cg01032398) or the Group 3 CpG (cg18768621) in the 3’ UTR in whole blood samples, with cognitive 
performance as assessed by delayed recall in individuals >60 years (Liu et al., 2018). However, it is 
worth noting that the published study was undertaken on blood samples, rather than brain tissue, and 
that they did not observe any associations with other cognitive measures. The authors did use a 
publically available resource to look at DNA methylation correlations of the APOE probes across 
matched brain and blood tissue and suggest that CpG sites that are highly methylated in blood are 
also so in many brain regions.  Interestingly, the 3 CpGs identified by Liu and colleagues (alongside 
cg18799241) have been reported to have a significant correlation of DNA methylation with APOE 
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gene expression in ENCODE data, which was not observed for the rest of the 13 CpG sites (Ma et al., 
2015). 
 
4.4 Age is associated with APOE methylation at cg21879725 in foetal brain tissue and 
at cg16471933 in post-natal brain tissue 
Finally, we observed a Bonferroni-significant decrease of DNA methylation at cg21879725, located in 
the CGI at the 3’ end of the UTR, with increasing developmental foetal developmental stage, while no 
Bonferroni-significant interaction between CpG methylation, age and genotype was apparent in post-
natal subjects. This CpG also showed a trend towards a mQTL with APOE genotype and towards an 
interaction of age and genotype, which marginally missed out on our stringent Bonferroni significance 
level. Our analyses highlighted that particularly in individuals possessing two APOE ε4 alleles there 
was a positive correlation of DNA methylation with increasing days post conception, which was not 
seen in individuals with fewer alleles. In the context of our AD results this is interesting as we saw 
altered DNA methylation in the 3’ UTR in AD brain samples. This may implicate APOE ε4 as a mQTL 
affecting foetal gene methylation that is conserved into adulthood, albeit with altered function, similar 
to foetal mQTLs implicated in other neurological diseases such schizophrenia that may exert foetal-
specific effects (Hannon et al., 2015), and introduce a new epigenetic biomarker for early prediction of 
disease risk. One potential reason that we did not quite reach Bonferroni significance in the pre-natal 
genotype analyses is because of the low number of foetal samples with an APOE ε4 genotype. It is 
therefore important that our findings are validated in a larger group of samples. In addition, we 
observed an inverse relationship in a heterozygous genotype, perhaps signifying the effect of a 
protective allele such as APOE ε3 (de-Almada et al., 2012). We also observed a Bonferroni-significant 
effect of age on DNA methylation at cg16471933 in post-natal brain samples, which is also located in 
the 3’ UTR CGI. However, this particular CpG site was not altered in the pre-natal samples with 
ageing. 
 
A positive association between APOE methylation at the 3’ UTR CGI and age / APOE ε4 genotype 
has already been noted by studies of mixed age cohorts (Foraker et al., 2015). Also a greater 
pathological effect has been previously seen to be exerted by APOE ε4 with increasing age (L.W. et 
al., 2016), which could be complimented by increased methylation in this region (Ma et al., 2015) 
although those studies were limited as they did not study methylation within foetal brain tissue. Our 
study was limited by fewer pre-natal samples than post-natal samples, making the inference of age 
methylation trends between the pre-natal and post-natal samples less reliable due to statistical power 
issues.  
 
4.5 Limitations of our study 
Our study represents a robust analysis of APOE DNA methylation in AD using multiple independent 
cohorts. However, there were some limitations with our study. First, our study is limited to the 13 CpG 
sites covered by the array, and it will be of interest to profile other methylation sites in the gene in the 
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future, including CpH sites. We acknowledge their limitations as part of the Illumina 450k manifest, 
and assignation based on functional annotation and linkage disequilibrium (LD) could have been more 
precise. However, our ultimate goal was to develop and confirm findings of our group’s previous 
APOE methylation studies based on the same Illumina probes (Lunnon et al., 2014), which 
themselves have been employed frequently in the literature and are thus generally accepted. In 
future, an improved approach could be an examination across APOE’s LD block at all CpG sites in 
the region. Yet another direction could be delving into the specific genomic contexts within which the 
aforementioned APOE CpGs are altered in AD.  
Second, we have used bisulfite-treated DNA, and thus our results reflect differences in total 
methylated cytosines, which is a sum of DNA methylation and hydroxymethylation. 5-
hydroxymethylcytosine (5hmC) is potentially a functionally discrete epigenetic marker that may have 
different effects on gene expression to 5mC. 5hmC has been found to be highly prevalent (and thus 
possibly epigenetically significant) in the neural epigenome, though its status as a unique mark or an 
intermediate state of methylation is controversial (Sanchez-Mut and Gräff, 2015). Interestingly, risk 
loci for AD have been found to show a trend towards enrichment near DMRs with reduced 5hmC in 
excitatory neurons and near enhancer regions in oligodendrocytes (Kozlenkov et al., 2018). Levels of 
5hmC are also very dynamic during foetal development (Spiers et al., 2017). Together, it will therefore 
be of interest to assess 5hmC levels in the APOE gene in both AD and pre-natal samples.  
 
Third, we used bulk tissue and so did not examine cell-specific gene methylation and it will be of 
interest to assess APOE DNA methylation in different brain cell types. Fourth, we limited our analyses 
to the STG and PFC and in the future the relationship of APOE DNA methylation and AD should be 
investigated in other brain regions. Interestingly, although we had more samples for the PFC, the 
most significant differences (and greater effect sizes) were observed in the STG and the biological 
basis of this should be further investigated. Fifth, our discovered methylation effects on 3’ APOE 
DMPs by diagnosis and disease pathology were minute, but may still exert a notable impact by 
aforementioned mechanisms, and could be further validated by cell-specific analyses to determine 
consistency in all types of neuronal cells, alongside studying the proportion/effect of 
hydroxymethylation in results. The relationship between cognitive decline and pathology development 
with differential methylation could also be further refined by quantifying any link between the rate of 
development of both to degrees of differential methylation in biopsied brain tissue. Sixth, we only 
assessed the relationship between methylation and genotype using the number of APOE ε4 alleles 
and it would be of interest to examine the relationship between the number of APOE ε2 alleles and 
DNA methylation for the 13 CpG sites, given that this genotype has been widely reported to be 
protective for AD risk (Wu and Zhao, 2016). However, although it has been associated with intact 
cognition, it has been reported to increase AD pathology in the oldest old (Berlau et al., 2009). In 
addition, given the study by Ma and colleagues shows rs05509 also alters DNA methylation, it will be 
of interest to study all SNPs in the APOE gene.  
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Seventh, our study of the effect of age and genotype on DNA methylation in the pre-natal cohort had 
limited sample numbers, particularly for APOE ε4 homozygotes, making inference of age or genotype-
associated methylation trends less reliable due to statistical power issues. Seventh, on the subject of 
statistical significance, Bonferroni tests assume independence between all tests performed. However, 
due to the high correlation between DNA methylation at adjacent CpG sites and multiple tissues from 
the same individuals, the tests are not fully independent. Therefore, by using a Bonferroni significance 
threshold we are being overly conservative. However, we acknowledge that by performing tests 
across multiple cohorts and tissues, the significance threshold could have been adjusted for this. 
Further to this, there were several outliers within our pre-natal methylation data for all genotype 
groups, which could possibly have skewed the methylation trends we observed and made subsequent 
extrapolations unreliable. Eighth, it would have been of interest to look at other outcomes (to 
diagnosis or Braak stage), as it is known that pathology does not always go hand in hand with specific 
cognitive deficits (Bilgel et al., 2018). In a similar vein we did not address the possibility of cooperative 
epigenetic mediation between Tau pathology and APOE ε4 genotype. Finally, although we have 
shown robust differences in APOE DNA methylation in the 3’ UTR CGI in AD, this does not appear to 
be driven by genetic variation. Therefore, we currently do not know whether the epigenetic differences 
we have identified are causal in disease pathogenesis, or are a consequence of the disease process 
and further research is required to clarify this. 
 
4.6 Conclusions 
Overall, our study has provided evidence of AD-associated hypomethylation of the APOE 3’ UTR CGI 
in AD cortex. Methylation of one site (cg21879725) in this region seems to be driven by APOE ε4 
genotype in pre-natal development, although this was not observed in post-natal samples. We did 
however identify another loci in this CGI that showed hypomethylation with age in post-natal samples 
(cg16471933). In the promoter at the 5’ end of the gene we observed three adjacent loci near the TSS 
(cg14123992, cg04406254, cg01032398) and one loci in the gene body (cg06750524) that were 
hypomethylated with advancing age in AD samples. Although the same direction of effect was seen in 
control individuals, this was not significant. In light of our current findings, future directions for our 
research would include bisulfite and oxidative- bisulfite sequencing in parallel of the APOE gene at 
single nucleotide resolution, to analyze which of these marks is present on the gene across its entire 
length (including CpH sites). It is also important to relate our epigenetic findings to gene expression 
and protein measurements in the same samples. Another avenue would be quantification of DNA 
modifications in specific neuronal/non-neuronal cell populations, utilizing a cell-sorting protocol akin to 
that used in a recent AD EWAS of purified neurons and glia (Gasparoni et al., 2018). It will be of 
interest to expand our study to look at other disease phenotypes, such as amyloid load or cognitive 
outcomes. In addition, it will be of interest to examine other APOE genotypes and SNPs for their 
relationship with methylation, as well as looking at allele-specific methylation. For the methylation 
sites not driven by genetic variation, it will be important to examine epigenetic causality using 
epigenetic editing in vitro. 
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Appendix 1 
#1. Data organisation 
## Data frames for analysis were constructed as follows: 
### 1.1 Reading in data 
library("wateRmelon") 
setwd("/mnt/data1/Leighton/LBBF/LBB") 
read.csv(file = "LBBF.dasen.betas.csv", header = TRUE, row.names = 1) -> 
LBBF_betas #Beta 
values of DMP analysis cohorts 
read.csv(file = "LBBFpheno.csv", header = TRUE, row.names = 1) -> LBBF_pheno 
#Phenotype 
data of DMP analysis cohorts 
LBBF_betas[c('cg01032398', 'cg04406254', 'cg05501958', 'cg06750524', 
'cg08955609', 
'cg12049787', 'cg14123992', 'cg16471933', 'cg18768621', 'cg18799241', 
'cg19514613', 
'cg21879725', 'cg26190885'), ] -> LBBF_probes 
sub("X", "", colnames (LBBF_probes)) -> colnames(LBBF_probes) 
t(LBBF_probes) -> LBBF_probes_reorganized 
merge(LBBF_probes_reorganized, LBBF_pheno, by = "row.names") -> 
LBBFpheno.2 
rownames(LBBFpheno.2)<-LBBFpheno.2$Row.names 
### 1.2 Inserting genotype data 
LBBFpheno.2[ ,c('APOE.genotype')] -> LBBF_genotype 
write.csv(LBBF_genotype, file = "LBBF_genotype.csv") 
read.csv(file = "LBBF_genotype2.csv", header = TRUE) -> LBBF_genotype 
cbind(LBBFpheno.2, LBBF_genotype)-> LBBFpheno.3 
### 1.3 Calculating and inserting cell proportion data 
setwd("/mnt/data1/reference_files/CETs/") 
install.packages("cets_0.99.2.tar.gz") 
library(cets) 
load("cetsBrain.rda") 
load("cetsDilution.rda") 
modelIdx <- list(neuron = pdBrain$celltype == "N", glia = pdBrain$celltype == 
"G") 
refProfile <- getReference(brain, modelIdx) 
head(refProfile) 
propLBB1F <- as.data.frame(estProportion(LBBF_betas, profile = refProfile)) 
colnames(propLBB1F)<-"cellprop" 
sub("X", "", rownames (propLBB1F)) -> rownames(propLBB1F) 
merge(LBBFpheno.3, propLBB1F, by="row.names")->LBBFpheno.4 
LBBFpheno.4$Row.names <- NULL 
rownames(LBBFpheno.4)<-LBBFpheno.4$Row.names 
### 1.4 Inserting Braak stage data 
LBBFpheno.2[, c('Analysis.2..Braak.Stage.')] -> LBBF_braak 
write.csv(LBBF_braak, file = 'LBBF_braak.csv') 
read.csv(file = 'LBBF_braak2.csv', header = TRUE) -> LBBF_braak 
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cbind(LBBFpheno.4, LBBF_braak)-> LBBFpheno.5 
head(LBBFpheno.5) 
### 1.5 Inserting diagnosis data 
LBBFpheno.2[, c('Analysis.1..AD.v.CTL.')] -> LBBF_diagnosis 
write.csv(LBBF_diagnosis, file = "LBBF_diagnosis.csv") 
read.csv(file = 'LBBF_diagnosis2.csv', header = TRUE) -> LBBF_diagnosis 
cbind(LBBFpheno.5, LBBF_diagnosis)-> LBBFpheno.6 
head(LBBFpheno.6) 
### 1.6 Inserting gender data 
LBBFpheno.2[, c('Gender')] -> LBBF_gender 
write.csv(LBBF_gender, file = "LBBF_gender.csv") 
read.csv(file = 'LBBF_gender2.csv', header = TRUE) -> LBBF_gender 
cbind(LBBFpheno.6, LBBF_gender) -> LBB1.F.pheno  
#Complete phenotype data frame 
 
# 2. Data QC and normalisation 
## QC and normalisation was conducted as follows: 
### 2.1 Loading in data 
library("wateRmelon") 
setwd("/mnt/data1/Leighton/LBBF/LBB") 
read.csv("LBBFpheno.csv", header=T, row.names=1)->LBBFpheno 
DataLBBF<-methylumIDAT(rownames(LBBFpheno),idatPath=getwd())  
#Raw data 
### 2.2 Quality control 
#### 2.2.1 Overall check of data: 
setwd(“/mnt/data1/Leighton/“) 
tiff(“test.tiff”) 
par(mar=c(6,2,1,1)+ 0.1) 
boxplot(log(methylated(DataLBBF)), las=2, cex.axis=0.6 , cex=0.6) 
dev.off() 
tiff(“test2.tiff”) 
par(mar=c(6,2,1,1)+ 0.1) 
boxplot(log(unmethylated(DataLBBF)), las=2, cex.axis=0.6 , cex=0.6) 
dev.off() 
### 2.3 Checking for odd samples/outliers/bad data/samples: 
#### 2.3.1 Sex check using X and Y chromosomes 
DataLBBF@featureData@data->FD 
betas(DataLBBF)-> DataLBBF.betas 
merge(FD, DataLBBF.betas, by = "row.names", all = TRUE)->DataLBBFFD 
t(DataLBBFFD)->DataLBBFFDt 
load("/mnt/data1/Bex/probesub.rda") 
probesub[probesub$CHR =="X",]->Xprobes 
Fmd <- cmdscale(dist(t(exprs(DataLBBF)[rownames(fData(DataLBBF)) %in% 
rownames(Xprobes),])),2) 
merge(LBBFpheno, Fmd, by = "row.names", all = TRUE)->LBBFXinfo 
tiff("sexcheckraw.tiff") 
plot(V2~V1,LBBFXinfo,col=(LBBFXinfo$Gender)) 
dev.off() 
### 2.4 Genotype checks using SNP probes 
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#### 2.4.1 Checking individual traces 
plot(density(DataLBBF.betas[,1], na.rm=T), ylim=c(0,4)) 
#### 2.4.2 Per sample density of beta values 
setwd("/mnt/data1/Leighton/") 
pdf(paste("DataLBBF_traces")) 
densityPlot(DataLBBF.betas) 
dev.off() 
#### 2.4.3 Average density of beta values 
pdf(paste("DataLBBF_traces_average")) 
plot(density(betas ,na.rm=T), ylim=c(0,4), col='black') 
dev.off() 
### 2.5 Filtering samples with >0.05 p-values in 5% of sites 
pfilter(DataLBBF, perc =5)->DataLBBF.pf 
### 2.6 Data Normalisation 
dasen(DataLBBF.pf)->DataLBBF.pf.dasen  
#The dasen function performs quantile normalisation of beta values 
### 2.7 Extraction of beta values 
betas(DataLBBF.pf.dasen)->LBBF.dasen.betas 
write.csv(LBBF.dasen.betas, file = "LBBF.dasen.betas.csv")  
#Final normalised and corrected beta values 
 
# 3. Analysis 
## Linear regression analyses for independent variables and methylation were 
conducted as follows: 
### 3.1 Braak stage analysis 
for (i in 2:14) { 
Braak_Regression <- lm(LBB1.F.pheno [, i]~Age + Gender + Cell_Proportion + 
Braak_Score, data = LBBFphenotype) 
print(summary(Braak_Regression)$coeff[,c(1,4)]) 
} 
### 3.2 Genotype analysis 
for (i in 2:14) { 
Genotype_Regression <- lm(LBB1.F.pheno [, i]~Age + Gender + Cell_Proportion + 
Genotype, data = LBBFphenotype) 
print(summary(Genotype_Regression)$coeff[,c(1,4)]) 
} 
### 3.3 Diagnosis analysis 
for (i in 2:14) { 
Diagnosis_Regression <- lm(LBB1.F.pheno [, i]~ Age + Gender + Cell_Proportion + 
Diagnosis, data = LBBFpheno.7) 
print(summary(Diagnosis_Regression)$coeff[,c(1,4)]) 
} 
### 3.4 Meta-analysis 
#### 3.4.1 Fisher's test of p-values for all cohorts 
library(MetaDE) 
read.csv(file = "Meta_Analysis2_p.csv", header = TRUE, row.names = NULL) -> 
Meta_p 
#Database of all cohort p-values 
as.matrix(Meta_p[, 2:53]) -> Meta_P 
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t(Meta_P) -> Meta_P 
list(p = Meta_P, bp = NULL) -> x 
MetaDE.pvalue(x, meta.method = c("Fisher"), rth = NULL, miss.tol = 0.3, asymptotic 
= FALSE) 
#### 3.4.2 Fisher's test of effect sizes for all cohorts 
read.csv(file = "New_Meta_Analysis2_es.csv", header = TRUE, row.names = 1) -> 
Meta_es 
#Database of all cohort effect sizes 
Meta_es[,1:52]-> Meta_es_2 
t(Meta_es_2)->Meta_es_3 
list(ES = Meta_es_3, Var = Probe_var, perm.ES = NULL) -> x 
MetaDE.ES(x, meta.method = c("FEM", "REM")) 
 
# 4. Example plotting 
## Plot type 1: Box-and-whisker plot 
tiff(file = 'STGCCBoxplot.tiff', units = 'cm', width = 50, height = 30, res = 300) 
#Plotting methylation % of CG probes with diagnosis in STG cohorts 
boxplot(Methylation~cgCC, xlab = 'CG Probes', ylab = 'Corrected % Methylation', col 
= c('forestgreen', 'lawngreen')) 
legend("topright", c("STG-AD", "STG-C"),fill=c('forestgreen','lawngreen')) 
dev.off() 
## Plot type 2: Manhattan plot 
input <- Manhattan_Table [,c('LBB.STG.Braak.p', 'LBB.STG.Braak.GP')]  
#Plotting Braak analysis p-values with genomic position of probes in London STG 
cohort 
print(head(input)) 
png(file = 'LBB.STG.Braak_plot.png') 
plot(x = input$LBB.STG.Braak.GP, y = input$LBB.STG.Braak.p, 
xlab = 'GP', 
ylab= 'p-value', 
xlim = c(45407868, 45412647), 
ylim = c(0.001, 13), 
) 
dev.off() 
## Plot type 3: Strip chart 
tiff(file = 'STGBraakStripchart1.tiff', units = 'cm', width = 50, height = 30, res = 300) 
#Plotting beta values of STG cohorts with Braak stage 
plot(LBBFSTGStrip[[1]]~bbscoreLBBFSTG, xlab = "Braak stage", ylab = 
'Methylation', 
col = c('forestgreen'), ylim = c(70, 90)) 
abline(lm(LBBFSTGStrip[[1]]~bbscoreLBBFSTG), lty = c(1), col = 'forestgreen') 
legend ("topright", c('London Brain Bank', 'Mount Sinai Brain Bank', 'Arizona Brain 
Bank'), pch = c(1, 0, 2), lty = c(1,2,3), col = 'forestgreen') 
points(MSSTGStrip[[1]]~bbscoreMSSTG, col = 'forestgreen', pch = 0) 
abline(lm(MSSTGStrip[[1]]~bbscoreMSSTG),lty=2, col="forestgreen") 
points(ArizonaSTGStrip[[1]]~bbscoreArizonaSTG, col = 'forestgreen', pch = 2) 
abline(lm(ArizonaSTGStrip[[1]]~bbscoreArizonaSTG), lty=3, col="forestgreen") 
dev.off() 
## Plot type 4: Effect size plot 
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plot.1 <- ggplot(data = MetaBraakSTG) #Plot of overall effect size of Braak stage on 
methylation in STG cohorts 
tiff("MetaBraakSTGggplot.tiff", units = "cm", width = 25, height = 25, res = 300) 
plot.1 + geom_point(alpha = 0.3,aes(x=MAPINFO, y=LBB_A_ESTOT.100, colour = 
"London")) 
+ 
geom_point(alpha = 0.3,aes(x=MAPINFO, y=MS_A_ESTOT.100, colour = "Mount 
Sinai"))+ 
geom_point(alpha = 0.3,aes(x=MAPINFO, y=ARIZ_A_ESTOT.100, colour = 
"Arizona"))+ 
geom_smooth(aes(x=MAPINFO, y=LBB_A_ESTOT.100, colour = "London"),se = 
FALSE) + 
geom_smooth(aes(x=MAPINFO, y=MS_A_ESTOT.100, colour = "Mount Sinai"),se = 
FALSE)+ 
geom_smooth(aes(x=MAPINFO, y=ARIZ_A_ESTOT.100, colour = "Arizona"),se = 
FALSE)+ 
theme(legend.justification=c(1,1), legend.position=c(1,1))+ xlab("Genomic Location") 
+ 
ylab("Methylation Effect Size") + scale_colour_discrete(name = "") 
dev.off() 
## Plot type 5: Scatter plot 
### Adjusted models for scatter plots were generated as follows: 
adjustedmodel <- function(Meth, measure1, measure2, measure3){ 
model <- lm(Meth ~ measure1 + measure2 + measure3) 
return(residuals(model) + coefficients(model)[1]) 
} 
#### Covariates: 
LBB1.F.pheno$Age..at.death. -> Age 
LBB1.F.pheno$Gender2 -> Gender 
LBB1.F.pheno$cellprop -> Cell_Proportion 
#### Independent variables: 
LBB1.F.pheno$bbscore -> Braak_Score 
LBB1.F.pheno$Diagnosis2 -> Diagnosis 
LBB1.F.pheno$APOE.genotype2 -> Genotype 
cg01032398 <-adjustedmodel(as.numeric(LBBFpheno.7[,2]), Age, Gender, 
Cell_Proportion) 
cg04406254 <- adjustedmodel(as.numeric(LBBFpheno.7[,3]), Age, Gender, 
Cell_Proportion) 
cg05501958 <- adjustedmodel(as.numeric(LBBFpheno.7[,4]), Age, Gender, 
Cell_Proportion) 
cg06750524 <- adjustedmodel(as.numeric(LBBFpheno.7[,5]), Age, Gender, 
Cell_Proportion) 
cg08955609 <- adjustedmodel(as.numeric(LBBFpheno.7[,6]), Age, Gender, 
Cell_Proportion) 
cg12049787 <- adjustedmodel(as.numeric(LBBFpheno.7[,7]), Age, Gender, 
Cell_Proportion) 
cg14123992 <- adjustedmodel(as.numeric(LBBFpheno.7[,8]), Age, Gender, 
Cell_Proportion) 
cg16471933 <- adjustedmodel(as.numeric(LBBFpheno.7[,9]), Age, Gender, 
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Cell_Proportion) 
cg18768621 <- adjustedmodel(as.numeric(LBBFpheno.7[,10]), Age, Gender, 
Cell_Proportion) 
cg18799241 <- adjustedmodel(as.numeric(LBBFpheno.7[,11]), Age, Gender, 
Cell_Proportion) 
cg19514613 <- adjustedmodel(as.numeric(LBBFpheno.7[,12]), Age, Gender, 
Cell_Proportion) 
cg21879725 <- adjustedmodel(as.numeric(LBBFpheno.7[,13]), Age, Gender, 
Cell_Proportion) 
cg26190885 <- adjustedmodel(as.numeric(LBBFpheno.7[,14]), Age, Gender, 
Cell_Proportion) 
LBBF_Adjusted_Model <- cbind(cg01032398, cg04406254, cg05501958, 
cg06750524, 
cg08955609, cg12049787, cg14123992, cg16471933, cg18768621, cg18799241, 
cg19514613, cg21879725, cg26190885) #Collating adjusted models into a single 
frame 
### Scatter graphs were plotted as follows: 
for (i in 1:13) { 
pdf(paste("LBBF_Probe_Braak_Graph", i)) 
plot(LBBF_Adjusted_Model [ ,i]~Braak_Score, xlab = "Braak score", ylab = "Adjusted 
beta values") #Plotting beta values with Braak score 
abline(lm(LBBF_Adjusted_Model[, i]~Braak_Score)) 
dev.off() 
} 
